,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,11,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
6,13,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
7,15,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
8,17,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
9,19,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
10,21,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
11,23,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
12,25,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
13,27,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
14,29,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
15,31,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
16,33,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
17,35,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
18,37,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
19,39,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
20,41,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
21,43,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
22,45,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
23,47,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
24,49,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
25,53,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
26,55,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
27,59,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
28,61,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
29,63,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
30,65,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
31,67,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
32,69,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
33,71,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
34,73,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
35,77,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
36,79,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
37,81,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
38,83,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
39,85,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
40,87,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
41,89,1,1,,420202,446541,Unspecified,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
42,91,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
43,93,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
44,95,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
45,97,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
46,99,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
47,101,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
48,103,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
49,105,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
50,107,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
51,109,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
52,113,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
53,115,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
54,119,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
55,121,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
56,123,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
57,125,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
58,129,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
59,131,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
60,133,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
61,137,1,1,,420202,446541,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
62,139,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
63,141,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
64,143,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
65,145,1,1,,420202,446541,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
66,155,1,1,,420202,446541,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
67,157,1,1,,420202,446541,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
68,161,1,1,,420202,446541,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
69,165,1,1,,420202,446541,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
70,167,1,1,,420202,446541,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
71,175,1,1,,420202,446541,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
72,179,1,1,,420202,446541,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
73,192,1,1,,420202,446541,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
74,198,1,1,,420202,446541,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in C57BL/6 mice,Other,,
75,226,1,1,,420202,446541,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in B6C3F1 mice,Other,,
76,248,1,1,,420202,446541,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
77,272,1,1,,420202,446541,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intramuscular) in B6D2F1 (BDF1) mice,Other,,
78,276,1,1,,420202,446541,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6C3F1 mice,Other,,
79,328,1,1,,420202,446541,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
80,330,1,1,,420202,446541,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
81,357,2,1,,11112696,446541,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
82,377,1,3,,10321763,446541,Inconclusive,42741659.0,5243.0,,,MDR-1,Other,,
83,410,1,5,,11112696,446541,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
84,410,1,5,,11112697,446541,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
85,410,1,5,,11114111,446541,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
86,411,2,1,,11112696,446541,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
87,411,2,1,,11112697,446541,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
88,411,2,1,,11114111,446541,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
89,444,1,1,,11112696,446541,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
90,445,3,1,,11112696,446541,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
91,445,3,1,,11112697,446541,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
92,445,3,1,,11114111,446541,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
93,446,1,1,,11112696,446541,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
94,447,1,1,,11112696,446541,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
95,447,1,1,,11112697,446541,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
96,447,1,1,,11114111,446541,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
97,448,1,2,,11112696,446541,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
98,448,1,2,,11112697,446541,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
99,448,1,2,,11114111,446541,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
100,450,1,2,,11112696,446541,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
101,450,1,2,,11112697,446541,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
102,450,1,2,,11114111,446541,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
103,451,1,2,,11112696,446541,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
104,451,1,2,,11112697,446541,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
105,451,1,2,,11114111,446541,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
106,526,1,1,,11112696,446541,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
107,526,1,1,,11112697,446541,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
108,526,1,1,,11114111,446541,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
109,530,1,1,,11112696,446541,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
110,530,1,1,,11112697,446541,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
111,530,1,1,,11114111,446541,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
112,584,1,3,,11112696,446541,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
113,584,1,3,,11112697,446541,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
114,584,1,3,,11114111,446541,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
115,585,1,4,,11112696,446541,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
116,585,1,4,,11112697,446541,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
117,585,1,4,,11114111,446541,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
118,587,1,5,,11112696,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
119,587,1,5,,11112697,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
120,588,1,4,,11112696,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
121,588,1,4,,11112697,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
122,589,1,3,,11112696,446541,Active,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
123,589,1,3,,11112697,446541,Active,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
124,590,1,3,,11112696,446541,Active,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
125,590,1,3,,11112697,446541,Active,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
126,591,1,4,,11112696,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
127,591,1,4,,11112697,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
128,592,1,6,,11112696,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
129,592,1,6,,11112697,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
130,593,1,4,,11112696,446541,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
131,593,1,4,,11112697,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
132,594,1,4,,11112696,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
133,594,1,4,,11112697,446541,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
134,595,1,3,,11112696,446541,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
135,595,1,3,,11112697,446541,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
136,595,1,3,,11114111,446541,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
137,596,1,2,,11112696,446541,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
138,596,1,2,,11112697,446541,Inconclusive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
139,596,1,2,,11114111,446541,Inconclusive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
140,597,1,3,,11112696,446541,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
141,597,1,3,,11112697,446541,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
142,597,1,3,,11114111,446541,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
143,603,1,2,,11112696,446541,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
144,603,1,2,,11112697,446541,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
145,603,1,2,,11114111,446541,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
146,605,1,2,,11112696,446541,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
147,605,1,2,,11112697,446541,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
148,605,1,2,,11114111,446541,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
149,607,1,3,,11112696,446541,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
150,607,1,3,,11112697,446541,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
151,607,1,3,,11114111,446541,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
152,608,1,6,,11537635,446541,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
153,662,1,1,,11112696,446541,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
154,662,1,1,,11112697,446541,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
155,662,1,1,,11114111,446541,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
156,875,1,2,,11112696,446541,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
157,875,1,2,,11114111,446541,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
158,880,2,1,,11112696,446541,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
159,880,2,1,,11112696,446541,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
160,880,2,1,,11114111,446541,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
161,880,2,1,,11114111,446541,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
162,880,2,1,,26747168,446541,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
163,880,2,1,,26747168,446541,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
164,880,2,1,,26752207,446541,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
165,880,2,1,,26752207,446541,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
166,880,2,1,,26752208,446541,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
167,880,2,1,,26752208,446541,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
168,880,2,1,,50104875,446541,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
169,880,2,1,,50104875,446541,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
170,881,2,2,,11112696,446541,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
171,881,2,2,,11114111,446541,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
172,881,2,2,,26752207,446541,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
173,883,1,3,,11112696,446541,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
174,883,1,3,,11112697,446541,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
175,883,1,3,,11114111,446541,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
176,884,1,2,,11112696,446541,Inconclusive,13435386.0,1576.0,10.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
177,884,1,2,,11114111,446541,Inconclusive,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
178,885,1,2,,11112696,446541,Inactive,13435386.0,1576.0,10.0,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
179,885,1,2,,11114111,446541,Inactive,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
180,886,1,2,,11112696,446541,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
181,886,1,2,,11112696,446541,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
182,886,1,2,,11112697,446541,Inconclusive,122921310.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
183,886,1,2,,11112697,446541,Inconclusive,122921311.0,,39.8107,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
184,886,1,2,,11114111,446541,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
185,886,1,2,,11114111,446541,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
186,887,1,2,,11112696,446541,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
187,887,1,2,,11114111,446541,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
188,889,1,3,,11112696,446541,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
189,889,1,3,,11114111,446541,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
190,891,1,2,,11112696,446541,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
191,891,1,2,,11112697,446541,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
192,891,1,2,,11114111,446541,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
193,892,1,2,,11112696,446541,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
194,892,1,2,,11114111,446541,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
195,893,1,2,,11112696,446541,Active,122921310.0,,12.5893,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
196,893,1,2,,11112696,446541,Active,122921311.0,,12.5893,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
197,893,1,2,,11114111,446541,Active,122921310.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
198,893,1,2,,11114111,446541,Active,122921311.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
199,894,2,1,,11112696,446541,Inconclusive,31542939.0,3248.0,14.1254,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
200,894,2,1,,11114111,446541,Inconclusive,31542939.0,3248.0,35.4813,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
201,894,2,1,,26747168,446541,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
202,894,2,1,,26752207,446541,Inconclusive,31542939.0,3248.0,28.1838,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
203,894,2,1,,50104875,446541,Inconclusive,31542939.0,3248.0,39.8107,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
204,899,1,2,,11112696,446541,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
205,899,1,2,,11112697,446541,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
206,899,1,2,,11114111,446541,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
207,900,1,3,,11112696,446541,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
208,900,1,3,,11114111,446541,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
209,901,1,2,,11112696,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
210,901,1,2,,11114111,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
211,902,1,2,,11112696,446541,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
212,902,1,2,,11114111,446541,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
213,910,1,2,,11114111,446541,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
214,912,1,2,,11112696,446541,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
215,912,1,2,,11112697,446541,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
216,912,1,2,,11114111,446541,Inconclusive,21392848.0,,1.2589,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
217,914,1,3,,11112696,446541,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
218,915,1,3,,11112696,446541,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
219,923,1,2,,11112696,446541,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
220,923,1,2,,11114111,446541,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
221,924,1,2,,11112696,446541,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
222,924,1,2,,11114111,446541,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
223,925,1,2,,11112696,446541,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
224,926,1,2,,11112696,446541,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
225,926,1,2,,11112697,446541,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
226,926,1,2,,11114111,446541,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
227,927,1,3,,11112696,446541,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
228,927,1,3,,11114111,446541,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
229,930,1,2,,11114111,446541,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
230,938,1,2,,11112696,446541,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
231,938,1,2,,11112697,446541,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
232,938,1,2,,11114111,446541,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
233,940,1,2,,26612017,446541,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
234,995,1,2,,11112696,446541,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
235,995,1,2,,11114111,446541,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
236,999,1,1,,46487929,446541,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
237,1004,1,1,,46487929,446541,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
238,1030,2,1,,11112696,446541,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
239,1030,2,1,,11114111,446541,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
240,1030,2,1,,26747168,446541,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
241,1030,2,1,,26752207,446541,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
242,1030,2,1,,26752208,446541,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
243,1030,2,1,,50104875,446541,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
244,1033,2,2,,11537635,446541,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
245,1332,1,1,,49698550,446541,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
246,1376,1,2,,47193743,446541,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
247,1379,1,2,,11112696,446541,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
248,1379,1,2,,11114111,446541,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
249,1379,1,2,,26747168,446541,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
250,1379,1,2,,26752207,446541,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
251,1379,1,2,,50104875,446541,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
252,1385,2,2,,47193743,446541,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
253,1422,1,1,,26612017,446541,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
254,1422,1,1,,47193743,446541,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
255,1452,1,1,,11112696,446541,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
256,1452,1,1,,11114111,446541,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
257,1452,1,1,,26752207,446541,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
258,1454,1,1,,11112696,446541,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
259,1454,1,1,,11114111,446541,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
260,1454,1,1,,26747168,446541,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
261,1454,1,1,,50104875,446541,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
262,1457,1,1,,11112696,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
263,1457,1,1,,11114111,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
264,1457,1,1,,26747168,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
265,1457,1,1,,26752207,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
266,1457,1,1,,26752208,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
267,1457,1,1,,50104875,446541,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
268,1458,1,1,,11112696,446541,Active,10937869.0,6607.0,0.5012,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
269,1458,1,1,,26747168,446541,Active,10937869.0,6607.0,0.631,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
270,1458,1,1,,26752208,446541,Active,10937869.0,6607.0,0.3981,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
271,1460,1,3,,11114111,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
272,1460,1,3,,26747168,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
273,1460,1,3,,26752207,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
274,1460,1,3,,26752208,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
275,1460,1,3,,50104875,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
276,1463,1,1,,11114111,446541,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
277,1463,1,1,,26747168,446541,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
278,1463,1,1,,26752207,446541,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
279,1463,1,1,,26752208,446541,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
280,1463,1,1,,50104875,446541,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
281,1465,1,1,,47193743,446541,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
282,1467,1,3,,11112696,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
283,1467,1,3,,11114111,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
284,1467,1,3,,26747168,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
285,1467,1,3,,26752207,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
286,1467,1,3,,50104875,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
287,1468,1,1,,11114111,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
288,1468,1,1,,26747168,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
289,1468,1,1,,26752207,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
290,1468,1,1,,26752208,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
291,1468,1,1,,50104875,446541,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
292,1469,1,1,,11112696,446541,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
293,1469,1,1,,11114111,446541,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
294,1469,1,1,,26747168,446541,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
295,1469,1,1,,26752207,446541,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
296,1469,1,1,,26752208,446541,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
297,1469,1,1,,50104875,446541,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
298,1471,2,1,,11112696,446541,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
299,1471,2,1,,11112697,446541,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
300,1471,2,1,,11114111,446541,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
301,1471,2,1,,26747168,446541,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
302,1471,2,1,,26752207,446541,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
303,1471,2,1,,26752208,446541,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
304,1471,2,1,,50104875,446541,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
305,1476,2,1,,11112696,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
306,1476,2,1,,11114111,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
307,1476,2,1,,26747168,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
308,1476,2,1,,26752207,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
309,1476,2,1,,50104875,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
310,1477,1,1,,11112696,446541,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
311,1477,1,1,,11114111,446541,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
312,1477,1,1,,26747168,446541,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
313,1477,1,1,,26752207,446541,Inconclusive,,,25.1189,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
314,1477,1,1,,26752208,446541,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
315,1477,1,1,,50104875,446541,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
316,1478,2,1,,11112696,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
317,1478,2,1,,11114111,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
318,1478,2,1,,26747168,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
319,1478,2,1,,26752207,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
320,1478,2,1,,50104875,446541,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
321,1479,1,2,,11112696,446541,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
322,1479,1,2,,11114111,446541,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
323,1479,1,2,,26747168,446541,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
324,1479,1,2,,26752207,446541,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
325,1479,1,2,,26752208,446541,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
326,1479,1,2,,50104875,446541,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
327,1487,1,1,,11112696,446541,Inconclusive,27436948.0,4000.0,0.1413,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
328,1490,2,1,,11112696,446541,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
329,1490,2,1,,11114111,446541,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
330,1490,2,1,,26747168,446541,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
331,1490,2,1,,26752207,446541,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
332,1490,2,1,,26752208,446541,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
333,1490,2,1,,50104875,446541,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
334,1498,1,1,,11112696,446541,Inconclusive,27436948.0,4000.0,0.631,Potency,Confirmation Concentration-Response Assay for Modulators of Lamin A Splicing,Confirmatory,,
335,1511,1,3,,47193743,446541,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
336,1519,1,3,,11112696,446541,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
337,1519,1,3,,11114111,446541,Inconclusive,,,35.4813,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
338,1519,1,3,,26747168,446541,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
339,1519,1,3,,50104875,446541,Inconclusive,,,6.3096,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
340,1529,1,1,,47193743,446541,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
341,1530,1,1,,47193743,446541,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
342,1531,1,1,,47193743,446541,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
343,1532,1,1,,47193743,446541,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
344,1549,1,2,,11537635,446541,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
345,1552,1,3,,11537635,446541,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
346,1554,1,1,,47193743,446541,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
347,1580,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
348,1581,1,1,,8149626,446541,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
349,1582,1,1,,8149626,446541,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
350,1583,1,1,,8149626,446541,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
351,1584,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
352,1585,1,1,,8149626,446541,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
353,1586,1,1,,8149626,446541,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
354,1587,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
355,1588,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
356,1589,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
357,1590,1,1,,8149626,446541,Active,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
358,1593,1,1,,8149626,446541,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
359,1594,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
360,1595,1,1,,8149626,446541,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
361,1596,1,1,,8149626,446541,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
362,1597,1,1,,8149626,446541,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
363,1598,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
364,1599,1,1,,8149626,446541,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
365,1600,1,1,,8149626,446541,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
366,1601,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
367,1602,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
368,1603,1,1,,8149626,446541,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
369,1604,1,1,,8149626,446541,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
370,1605,1,1,,8149626,446541,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
371,1606,1,1,,8149626,446541,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
372,1607,1,1,,8149626,446541,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
373,1608,1,1,,8149626,446541,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
374,1609,1,1,,8149626,446541,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
375,1610,1,1,,8149626,446541,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
376,1611,1,1,,8149626,446541,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
377,1612,1,1,,8149626,446541,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
378,1613,1,1,,8149626,446541,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
379,1614,1,1,,8149626,446541,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
380,1616,1,1,,8149626,446541,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
381,1621,1,2,,47193743,446541,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
382,1626,1,2,,47193743,446541,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
383,1637,1,2,,11537635,446541,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
384,1648,1,2,,11537635,446541,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
385,1650,1,2,,47193743,446541,Active,,,4.61,CC50,A Cell Based Secondary Assay To Explore Cytotoxicity of West Nile Virus Anti-Viral Hit Compounds,Confirmatory,,
386,1662,1,2,,47193743,446541,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
387,1663,1,2,,47193743,446541,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
388,1672,1,3,,47193743,446541,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
389,1688,1,1,,11112696,446541,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
390,1733,1,1,,11112696,446541,Inactive,,,,Potency,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Interaction with Luciferase Reporter,Confirmatory,,
391,1733,1,1,,11114111,446541,Inactive,,,,Potency,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Interaction with Luciferase Reporter,Confirmatory,,
392,1733,1,1,,26747168,446541,Inactive,,,,Potency,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Interaction with Luciferase Reporter,Confirmatory,,
393,1733,1,1,,50104875,446541,Inactive,,,,Potency,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Interaction with Luciferase Reporter,Confirmatory,,
394,1739,1,1,,11112696,446541,Active,4507091.0,6606.0,,,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Modulation of SMN1 Expression,Confirmatory,,
395,1739,1,1,,11114111,446541,Active,4507091.0,6606.0,,,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Modulation of SMN1 Expression,Confirmatory,,
396,1739,1,1,,26747168,446541,Active,4507091.0,6606.0,,,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Modulation of SMN1 Expression,Confirmatory,,
397,1739,1,1,,50104875,446541,Active,4507091.0,6606.0,,,Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Modulation of SMN1 Expression,Confirmatory,,
398,1740,1,1,,11112696,446541,Inconclusive,10937869.0,6607.0,0.1585,Potency,Confirmation Concentration-Response Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
399,1740,1,1,,11114111,446541,Inconclusive,10937869.0,6607.0,0.1,Potency,Confirmation Concentration-Response Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
400,1740,1,1,,26747168,446541,Inconclusive,10937869.0,6607.0,0.3548,Potency,Confirmation Concentration-Response Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
401,1740,1,1,,50104875,446541,Inconclusive,10937869.0,6607.0,0.0631,Potency,Confirmation Concentration-Response Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
402,1766,1,1,,11112696,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
403,1766,1,1,,11112696,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
404,1766,1,1,,11114111,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
405,1766,1,1,,11114111,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
406,1766,1,1,,26747168,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
407,1766,1,1,,26747168,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
408,1766,1,1,,26752207,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
409,1766,1,1,,26752207,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
410,1766,1,1,,50104875,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
411,1766,1,1,,50104875,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
412,1768,1,1,,11112696,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
413,1768,1,1,,11112696,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
414,1768,1,1,,11114111,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
415,1768,1,1,,11114111,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
416,1768,1,1,,26747168,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
417,1768,1,1,,26747168,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
418,1768,1,1,,26752207,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
419,1768,1,1,,26752207,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
420,1768,1,1,,50104875,446541,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
421,1768,1,1,,50104875,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
422,1811,3,2,,46392307,446541,Active,15826575.0,,,,Experimentally measured binding affinity data derived from PDB,Other,8681386.0,
423,1813,1,2,,47193743,446541,Active,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
424,1814,1,2,,47193743,446541,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
425,1832,2,1,,47193743,446541,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
426,1850,2,1,,47193743,446541,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
427,1851,1,2,,11112696,446541,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
428,1851,1,2,,11114111,446541,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
429,1851,1,2,1.0,11112696,446541,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
430,1851,1,2,1.0,11114111,446541,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
431,1851,1,2,2.0,11112696,446541,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
432,1851,1,2,2.0,11114111,446541,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
433,1851,1,2,3.0,11112696,446541,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
434,1851,1,2,3.0,11114111,446541,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
435,1851,1,2,4.0,11112696,446541,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
436,1851,1,2,4.0,11114111,446541,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
437,1851,1,2,5.0,11112696,446541,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
438,1851,1,2,5.0,11114111,446541,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
439,1863,2,1,,47193743,446541,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
440,1865,1,1,,11112696,446541,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
441,1865,1,1,,11114111,446541,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
442,1865,1,1,,26747168,446541,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
443,1865,1,1,,26752207,446541,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
444,1865,1,1,,26752208,446541,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
445,1865,1,1,,50104875,446541,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
446,1875,2,1,,47193743,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
447,1885,2,1,,47193743,446541,Active,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
448,1899,1,3,,47193743,446541,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
449,1903,2,3,,47193743,446541,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
450,1906,1,3,,47193743,446541,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
451,1910,1,2,,47193743,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
452,1947,1,2,,47193743,446541,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
453,1948,1,1,,11112696,446541,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
454,1948,1,1,,11114111,446541,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
455,1948,1,1,,26747168,446541,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
456,1948,1,1,,26752207,446541,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
457,1948,1,1,,50104875,446541,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
458,1950,1,3,,47193743,446541,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
459,1956,1,1,,47193743,446541,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
460,1962,1,2,,47193743,446541,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
461,1974,1,2,,47193743,446541,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
462,1979,1,1,,47193743,446541,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
463,1987,1,2,,47193743,446541,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
464,1988,1,2,,47193743,446541,Active,,,8.195,EC50,Luminescence Cell-Based Dose Confimation HTS to Identify Inhibitors of of 5'UTR Stem-Loop Driven Alpha-Synuclein mRNA Translation in H4 Neuroglioblastoma Cells,Confirmatory,,
465,1990,1,2,,47193743,446541,Active,,,10.152999999999999,EC50,Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of Luciferase Translation or Activity in H4 Neuroglioblastoma Cells,Confirmatory,,
466,1994,1,2,,47193743,446541,Active,,,0.11599999999999999,EC50,Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of 5'UTR Stem-Loop Driven Prion Protein mRNA Translation in H4 Neuroglioblastoma Cells,Confirmatory,,
467,2010,1,2,,47193743,446541,Active,,,10.862,EC50,Luminescence Cell-Based Dose Response HTS Screen to Identify Cytotoxic Compounds of NIH3T3 cells.,Confirmatory,,
468,2016,1,3,,47193743,446541,Active,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
469,2023,1,3,,47193743,446541,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
470,2025,1,3,,47193743,446541,Active,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
471,2029,1,3,,47193743,446541,Inconclusive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
472,2044,1,1,,47193743,446541,Active,,,1.643,EC50,Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of T.Cruzi Replication.,Confirmatory,,
473,2052,2,1,,47193743,446541,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
474,2057,1,2,,47193743,446541,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
475,2066,1,4,,47193743,446541,Inconclusive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
476,2094,1,2,,47193743,446541,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
477,2094,1,2,,47193743,446541,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
478,2094,1,2,,47193743,446541,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
479,2097,1,2,,47193743,446541,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
480,2098,1,1,,47193743,446541,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
481,2099,1,1,,47193743,446541,Inconclusive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
482,2101,1,1,,11112696,446541,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
483,2101,1,1,,11114111,446541,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
484,2101,1,1,,26747168,446541,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
485,2101,1,1,,26752207,446541,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
486,2101,1,1,,26752208,446541,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
487,2101,1,1,,50104875,446541,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
488,2107,1,1,,11112696,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
489,2107,1,1,,11114111,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
490,2107,1,1,,26747168,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
491,2107,1,1,,26752207,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
492,2107,1,1,,26752208,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
493,2107,1,1,,50104875,446541,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
494,2112,1,1,,11112696,446541,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
495,2112,1,1,,11114111,446541,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
496,2112,1,1,,26747168,446541,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
497,2112,1,1,,26752207,446541,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
498,2112,1,1,,26752208,446541,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
499,2112,1,1,,50104875,446541,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
500,2129,1,2,,47193743,446541,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
501,2130,1,3,,47193743,446541,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
502,2147,1,1,,11112696,446541,Inconclusive,221046486.0,,8.9125,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
503,2147,1,1,,11114111,446541,Inconclusive,221046486.0,,35.4813,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
504,2147,1,1,,26747168,446541,Inconclusive,221046486.0,,28.1838,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
505,2147,1,1,,50104875,446541,Inconclusive,221046486.0,,35.4813,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
506,2156,2,2,,47193743,446541,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
507,2174,1,3,,47193743,446541,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
508,2177,1,3,,47193743,446541,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
509,2216,1,3,,47193743,446541,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
510,2221,1,2,,47193743,446541,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
511,2227,1,2,,47193743,446541,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
512,2234,1,2,,47193743,446541,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
513,2235,1,2,,47193743,446541,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
514,2237,1,2,,47193743,446541,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
515,2239,1,2,,47193743,446541,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
516,2240,1,1,,85787933,446541,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
517,2241,1,1,,85787933,446541,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
518,2247,1,2,,47193743,446541,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
519,2275,1,1,,85787933,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
520,2280,2,3,,47193743,446541,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
521,2300,1,3,,47193743,446541,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
522,2313,1,1,,85787933,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
523,2316,1,1,,85787933,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
524,2322,1,1,,85787933,446541,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
525,2330,1,1,,85787933,446541,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
526,2380,1,2,,47193743,446541,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
527,2435,1,2,,47193743,446541,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
528,2445,1,2,,47193743,446541,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
529,2451,1,2,,11112696,446541,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
530,2451,1,2,,11114111,446541,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
531,2451,1,2,,26747168,446541,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
532,2451,1,2,,26752207,446541,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
533,2451,1,2,,50104875,446541,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
534,2462,1,1,,47193743,446541,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
535,2462,1,1,,47193743,446541,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
536,2472,1,2,,11112696,446541,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
537,2472,1,2,,11114111,446541,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
538,2472,1,2,,26747168,446541,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
539,2472,1,2,,26752207,446541,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
540,2472,1,2,,50104875,446541,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
541,2517,2,1,,11114111,446541,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
542,2517,2,1,,26747168,446541,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
543,2517,2,1,,26752207,446541,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
544,2517,2,1,,26752208,446541,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
545,2517,2,1,,50104875,446541,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
546,2517,2,1,,144204161,446541,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
547,2520,1,4,,47193743,446541,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
548,2521,1,3,,47193743,446541,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
549,2524,1,2,,47193743,446541,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
550,2528,1,2,,11112696,446541,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
551,2528,1,2,,11114111,446541,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
552,2528,1,2,,26747168,446541,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
553,2528,1,2,,26752207,446541,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
554,2528,1,2,,50104875,446541,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
555,2540,1,2,,47193743,446541,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
556,2544,1,2,,47193743,446541,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
557,2546,1,1,,11112696,446541,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
558,2546,1,1,,11114111,446541,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
559,2546,1,1,,26747168,446541,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
560,2546,1,1,,26752207,446541,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
561,2546,1,1,,50104875,446541,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
562,2549,1,1,,11112696,446541,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
563,2549,1,1,,11114111,446541,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
564,2549,1,1,,26747168,446541,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
565,2549,1,1,,26752207,446541,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
566,2549,1,1,,26752208,446541,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
567,2549,1,1,,50104875,446541,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
568,2550,1,3,,47193743,446541,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
569,2551,1,1,,11112696,446541,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
570,2551,1,1,,11114111,446541,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
571,2551,1,1,,26747168,446541,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
572,2551,1,1,,26752207,446541,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
573,2551,1,1,,50104875,446541,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
574,2553,1,2,,47193743,446541,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
575,2557,1,3,,47193743,446541,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
576,2563,1,1,,47193743,446541,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
577,2599,1,2,,47193743,446541,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
578,2606,1,2,,47193743,446541,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
579,2629,1,1,,47193743,446541,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
580,2642,1,2,,47193743,446541,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
581,2648,1,2,,47193743,446541,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
582,2650,2,1,,47193743,446541,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
583,2661,1,1,,47193743,446541,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
584,2662,2,1,,11112696,446541,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
585,2690,1,2,,47193743,446541,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
586,2716,1,1,,47193743,446541,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
587,2717,1,2,,47193743,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
588,2718,1,1,,47193743,446541,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
589,2751,2,2,,47193743,446541,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
590,2796,1,4,,47193743,446541,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
591,2797,1,2,,47193743,446541,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
592,2805,2,2,,47193743,446541,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
593,2806,2,2,,47193743,446541,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
594,2825,1,2,,47193743,446541,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
595,8670,6,3,,103226686,446541,Active,,,0.4,IC50,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Confirmatory,,
596,45812,6,2,,103226686,446541,Active,,,0.34,IC50,In vitro secondary T-cell (CEM) proliferation assay,Confirmatory,12014950.0,
597,46396,8,1,,103226686,446541,Active,,,0.34,IC50,Inhibition of CEM (human leukemia) cell proliferation.,Confirmatory,14505670.0,
598,46559,6,3,,103226686,446541,Active,,,0.9,IC50,Cytotoxic activity against HIV uninfected T4 lymphocytes (CEM cell line),Confirmatory,,
599,46578,6,2,,103226686,446541,Active,,,0.39,IC50,Inhibitory activity against CEM cell proliferation,Confirmatory,12565968.0,
600,46583,6,2,,103226686,446541,Active,,,0.39,IC50,Inhibitory activity against proliferation of CEM cell line,Confirmatory,12565969.0,
601,46936,3,5,,103226686,446541,Unspecified,,,,,Antitumor activity against HIV infected T4 lymphocytes (CEM cell line) at 0.4 uM concentration,Other,,
602,83755,6,2,,103226686,446541,Active,,,0.4,IC50,Inhibitory activity of compound against HT-29 human colon adenocarcinoma cell line,Confirmatory,8568826.0,
603,83933,6,3,,103226686,446541,Active,,,0.9,IC50,In vitro antitumor activity against HT-29 human colon adenocarcinoma cells,Confirmatory,,
604,89839,6,2,,103226686,446541,Active,,,0.057999999999999996,IC50,Inhibition of human Lymphocyte proliferation. The IC50 values were determined by interpolation using cubic spline determination.,Confirmatory,8863796.0,
605,90469,6,2,,103226686,446541,Active,,,0.06,IC50,In vitro inhibition of human lymphocyte proliferation in response to phytohemagglutininin (PHA) was determined,Confirmatory,1967654.0,
606,90470,6,2,,103226686,446541,Active,,,0.02,IC50,In vitro inhibition of human lymphocyte proliferation in response to pokeweed mitogen(PWM) was determined,Confirmatory,1967654.0,
607,90471,6,2,,103226686,446541,Active,,,0.06,IC50,In vitro inhibition of human lymphocyte proliferation in response to staphylococcus protein A(SPA) was determined,Confirmatory,1967654.0,
608,91401,9,2,,103226686,446541,Active,,,20.0,IC50,Inhibitory activity against (IMPDH) inosine 5'-monophosphate dehydrogenase,Confirmatory,12729643.0,
609,91402,11,2,,103226686,446541,Active,124419.0,3615.0,0.015,IC50,Inhibition of Inosine Monophosphate Dehydrogenase II (IMPDH II),Confirmatory,12372516.0,
610,92486,10,5,,103226686,446541,Active,25014074.0,3614.0,0.02,IC50,In vitro inhibition of inosine Inosine-5'-monophosphate dehydrogenase,Confirmatory,1967654.0,
611,92606,9,2,,103226686,446541,Active,,,0.055,IC50,Inhibitory activity against inosine monophosphate dehydrogenase IMPDH type I,Confirmatory,12565968.0,
612,92607,9,1,,103226686,446541,Active,,,0.033,Ki,Inhibitory activity against human Inosine-5'-monophosphate dehydrogenase 1 (IMPDH type I isoform); Range is 33-37 nM,Confirmatory,9484510.0,
613,92608,9,2,,103226686,446541,Active,,,0.04,Ki,Inhibitory activity against human Inosine-5'-monophosphate dehydrogenase 1 (IMPDH type I),Confirmatory,11806722.0,
614,92616,11,1,,103226686,446541,Active,,,0.0251,IC50,Compound was tested for inhibition of human recombinant type II Inosine Monophosphate Dehydrogenase at pH 7.4,Confirmatory,8863796.0,
615,92617,11,1,,103226686,446541,Active,,,0.0248,IC50,Compound was tested for inhibition of human recombinant type II Inosine Monophosphate Dehydrogenase at pH 8.0,Confirmatory,8863796.0,
616,92622,7,2,,103226686,446541,Active,,,0.013999999999999999,IC50,Inhibition of human inosine-5'-monophosphate dehydrogenase 2,Confirmatory,12014950.0,
617,92624,9,2,,103226686,446541,Active,,,0.013999999999999999,IC50,Inhibition of human inosine monophosphate dehydrogenase IMPDH II,Confirmatory,12565968.0,
618,92740,9,2,,103226686,446541,Active,,,0.013999999999999999,IC50,Inhibitory activity against inosine monophosphate dehydrogenase IMPDH II,Confirmatory,12565969.0,
619,92741,11,1,,103226686,446541,Active,,,0.015,IC50,Inhibition of human Inosine-5'-monophosphate dehydrogenase 2,Confirmatory,12127522.0,
620,92742,11,1,,103226686,446541,Active,,,0.015,IC50,Inhibitory activity tested against inosine-5'-monophosphate dehydrogenase 2 (IMPDH-II) enzyme,Confirmatory,14505670.0,
621,92743,11,1,,103226686,446541,Active,,,0.015,IC50,Inhibitory concentration against Inosine-5'-monophosphate dehydrogenase 2 was determined,Confirmatory,12392738.0,
622,92745,9,2,,103226686,446541,Active,,,0.015,IC50,In vitro inhibition of Inosine-5'-monophosphate dehydrogenase 2.,Confirmatory,12270177.0,
623,92748,9,1,,103226686,446541,Active,,,0.006,Ki,Inhibitory activity against human Inosine-5'-monophosphate dehydrogenase 2 (IMPDH type II isoform); Range is 6-10 nM,Confirmatory,9484510.0,
624,92749,9,2,,103226686,446541,Active,,,0.01,Ki,Inhibitory activity against human Inosine-5'-monophosphate dehydrogenase 2 (IMPDH type II),Confirmatory,11806722.0,
625,95166,6,2,,103226686,446541,Active,,,0.08,IC50,Inhibitory activity against growth of human erythroleukemia K652 cells,Confirmatory,9484510.0,
626,95608,6,2,,103226686,446541,Active,,,0.3,Ki,Antiproliferative activity against K562 cells,Confirmatory,11806722.0,
627,96712,6,3,,103226686,446541,Active,,,0.2,IC50,In vitro antitumor activity against L1210 murine lymphocytic leukemia cells,Confirmatory,,
628,98904,6,2,,103226686,446541,Active,,,0.2,IC50,Inhibitory activity of compound against L1210 leukemia cells in tissue culture,Confirmatory,8568826.0,
629,103597,6,3,,103226686,446541,Active,,,0.5,IC50,In vitro antitumor activity against MCF-7 human breast adenocarcinoma cells,Confirmatory,,
630,114692,6,2,,103226686,446541,Unspecified,,,,,Effective dose was measured in mice as concentration required to inhibit 50% inhibition of Murine PFC response,Other,8863796.0,
631,115873,3,3,,103226686,446541,Unspecified,,,,,Tested for the inhibition of murine PFC response at 12.5 mg/kg dose,Other,8863796.0,
632,115874,3,3,,103226686,446541,Unspecified,,,,,Tested for the inhibition of murine PFC response at 25 mg/kg dose,Other,8863796.0,
633,115875,3,3,,103226686,446541,Unspecified,,,,,Tested for the inhibition of murine PFC response at 50 mg/kg dose,Other,8863796.0,
634,115876,3,3,,103226686,446541,Unspecified,,,,,Tested for the inhibition of murine PFC response at 6.25 mg/kg dose,Other,8863796.0,
635,118202,3,4,,103226686,446541,Unspecified,,,,,"Inhibition of Murine plaque forming cells response, activity expressed as Potency Relative to 1a",Other,8863796.0,
636,134134,3,4,,103226686,446541,Unspecified,,,,,In vivo antibody response to sheep red blood cells(SRBC) by plaque-forming cells in the spleen (PFC/spleen) after 25 mg/kg oral administration in mice.,Other,1967654.0,
637,134137,3,3,,103226686,446541,Unspecified,,,,,In vivo antibody response to sheep red blood cells(SRBC) by plaques per million after 25 mg/kg oral administration in mice.,Other,1967654.0,
638,134138,3,4,,103226686,446541,Unspecified,,,,,In vivo for antibody response to sheep red blood cells(SRBC) by plaque-forming cells in the spleen (PFC/spleen) after 25 mg/kg oral administration in mice.,Other,1967654.0,
639,134472,3,3,,103226686,446541,Unspecified,,,,,In vivo antibody response to sheep red blood cells(SRBC) by plaques per million after 25 mg/kg oral administration in mice.,Other,1967654.0,
640,134852,4,4,,103226686,446541,Unspecified,,,,,In vivo inhibition of plaque-forming cells in the spleen (PFC/spleen) after 25 mg/kg oral administration in mice.,Other,1967654.0,
641,134854,4,3,,103226686,446541,Unspecified,,,,,In vivo inhibition of plaques per million after 25 mg/kg oral administration in mice.,Other,1967654.0,
642,155457,6,2,,103226686,446541,Active,,,0.6,IC50,Inhibitory activity against proliferation of peripheral blood mononuclear cells,Confirmatory,12565969.0,
643,157180,6,3,,103226686,446541,Active,,,0.7,IC50,In vitro antitumor activity against PSN-1 human pancreatic carcinoma cells,Confirmatory,,
644,195367,6,2,,103226686,446541,Active,,,1.0,IC50,Inhibitory activity against the PDGF-induced proliferation of rat aortic smooth muscle cell (RAoSMC),Confirmatory,15177474.0,
645,210303,6,2,,103226686,446541,Active,,,0.39,IC50,Inhibitory activity against human T-lymphoblast CEM cell line using T cell proliferation assay,Confirmatory,12127522.0,
646,210304,6,2,,103226686,446541,Active,,,0.39,IC50,Inhibitory concentration against human T-lymphoblast CEM cell line (ATCC) by CEM proliferation assay.,Confirmatory,12270177.0,
647,210432,6,2,,103226686,446541,Active,,,0.39,IC50,The human T-lymphoblastCEM cell (ATCC) proliferation inhibitory activity was determined,Confirmatory,12270168.0,
648,226618,3,9,,103226686,446541,Unspecified,,,,,Ratio of IC50(Type I) to IC50(Type II),Other,12565968.0,
649,261583,6,2,,103226686,446541,Active,,,1.4,EC50,Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line,Confirmatory,16539402.0,
650,261586,6,2,,103226686,446541,Active,,,0.04,EC50,Inhibition of Rluc-FL-WNV replicon in Vero cells,Confirmatory,16539402.0,
651,261589,6,2,,103226686,446541,Active,,,0.04,EC50,Inhibition of West Nile virus VLP replicon in BHK21 cell line,Confirmatory,16539402.0,
652,261590,6,2,,103226686,446541,Active,,,0.08,EC50,Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells,Confirmatory,16539402.0,
653,264222,4,4,,103226686,446541,Active,,,0.0992,IC50,Antiproliferative activity against HUVEC as measured by [3H]thymidine incorporation,Confirmatory,16640327.0,
654,264223,4,4,,103226686,446541,Active,,,0.128,IC50,Antiproliferative activity against Jurkat T cells as measured by [3H]thymidine incorporation,Confirmatory,16640327.0,
655,264224,3,4,,103226686,446541,Inactive,,,,,Antiproliferative activity against HUVEC in presence of 20 uM guanine as measured by [3H]thymidine incorporation,Other,16640327.0,
656,264225,3,4,,103226686,446541,Inactive,,,,,Antiproliferative activity against Jurkat T cells in presence of 20 uM guanine as measured by [3H]thymidine incorporation,Other,16640327.0,
657,264226,3,4,,103226686,446541,Unspecified,,,,,Cell cycle arrest at G1 phase in HUVEC at 1 uM,Other,16640327.0,
658,264227,3,4,,103226686,446541,Unspecified,,,,,Cell cycle arrest at S phase in HUVEC at 1 uM,Other,16640327.0,
659,264228,3,4,,103226686,446541,Unspecified,,,,,Cell cycle arrest at G2/M phase in HUVEC at 1 uM,Other,16640327.0,
660,264229,3,4,,103226686,446541,Unspecified,,,,,Cell cycle arrest at G1 phase in HUVEC at 1 uM in presence of 50 uM guanosine,Other,16640327.0,
661,264230,3,4,,103226686,446541,Unspecified,,,,,Cell cycle arrest at S phase in HUVEC at 1 uM in presence of 50 uM guanosine,Other,16640327.0,
662,264231,3,4,,103226686,446541,Unspecified,,,,,Cell cycle arrest at G2/M phase in HUVEC at 1 uM in presence of 50 uM guanosine,Other,16640327.0,
663,264232,3,3,,103226686,446541,Unspecified,,,,,"Antiangiogenic activity in mouse at 60 mg/kg/day, sc",Other,16640327.0,
664,264233,4,3,,103226686,446541,Unspecified,,,,,Inhibition of tumor-induced angiogenesis in RENCA mouse model,Other,16640327.0,
665,267725,8,5,,103226686,446541,Active,25014074.0,3614.0,0.032,IC50,Inhibition of human IMPDH1,Confirmatory,16621550.0,
666,267726,8,5,,103226686,446541,Active,124419.0,3615.0,0.011000000000000001,IC50,Inhibition of human IMPDH2,Confirmatory,16621550.0,
667,267727,3,11,,103226686,446541,Unspecified,124419.0,3615.0,,,Selectivity for IMPDH1 over IMPDH2,Other,16621550.0,
668,267727,3,11,,103226686,446541,Unspecified,25014074.0,3614.0,,,Selectivity for IMPDH1 over IMPDH2,Other,16621550.0,
669,278351,4,3,,103226686,446541,Unspecified,,,,,Inhibition of viral RNA levels in HTNV76-118-infected Vero E6 cells at 10 ug/ml,Other,17060520.0,
670,278353,3,4,,103226686,446541,Unspecified,,,,,Decrease in GTP level in Vero E6 cells at 2.5 ug/ml,Other,17060520.0,
671,278359,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 10 ug/ml RBV in Vero E6 cells assessed as RBV-MP concentration at 1 ug/ml after 24 h,Other,17060520.0,
672,278360,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 10 ug/ml RBV in Vero E6 cells assessed as RBV-MP concentration at 2 ug/ml after 24 h,Other,17060520.0,
673,278361,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 10 ug/ml RBV in Vero E6 cells assessed as RBV-MP concentration at 5 ug/ml after 24 h,Other,17060520.0,
674,278363,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 40 ug/ml RBV in Vero E6 cells assessed as RBV-MP concentration at 1 ug/ml after 24 h,Other,17060520.0,
675,278364,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 40 ug/ml RBV in Vero E6 cells assessed as RBV-MP concentration at 2 ug/ml after 24 h,Other,17060520.0,
676,278365,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 40 ug/ml RBV in Vero E6 cells assessed as RBV-MP concentration at 5 ug/ml after 24 h,Other,17060520.0,
677,278369,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 10 ug/ml RBV in Vero E6 cells assessed as RBV-TP concentration at 1 ug/ml after 24 h,Other,17060520.0,
678,278370,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 10 ug/ml RBV in Vero E6 cells assessed as RBV-TP concentration at 2 ug/ml after 24 h,Other,17060520.0,
679,278371,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 10 ug/ml RBV in Vero E6 cells assessed as RBV-TP concentration at 5 ug/ml after 24 h,Other,17060520.0,
680,278373,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 40 ug/ml RBV in Vero E6 cells assessed as RBV-TP concentration at 1 ug/ml after 24 h,Other,17060520.0,
681,278374,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 40 ug/ml RBV in Vero E6 cells assessed as RBV-TP concentration at 2 ug/ml after 24 h,Other,17060520.0,
682,278375,7,1,,103226686,446541,Unspecified,,,,,Effect on metabolism of 40 ug/ml RBV in Vero E6 cells assessed as RBV-TP concentration at 5 ug/ml after 24 h,Other,17060520.0,
683,278379,3,4,,103226686,446541,Unspecified,,,,,Decrease in GTP level in Vero E6 cells at 40 ug/ml after 24 h,Other,17060520.0,
684,292039,8,1,,103226686,446541,Active,,,0.54,IC50,Inhibition of CEM cell proliferation,Confirmatory,17585753.0,
685,292040,8,5,,103226686,446541,Active,124419.0,3615.0,0.016,IC50,Inhibition of human IMPDH2,Confirmatory,17585753.0,
686,292041,8,1,,103226686,446541,Active,,,0.13,IC50,Inhibition of T cell proliferation in PBMC cells,Confirmatory,17585753.0,
687,300648,7,1,,103226686,446541,Active,,,,,Inhibition of mouse 3T3-L1 cell differentiation assessed as minimal effective concentration at 2 uM by oil-red O staining method,Other,17618115.0,
688,300649,3,4,,103226686,446541,Active,,,,,Inhibition of mouse 3T3-L1 cell differentiation at 0.2 uM,Other,17618115.0,
689,300650,3,10,,103226686,446541,Unspecified,13432234.0,5468.0,,,Inhibition of [1-14C]sodium acetate uptake at PPARgamma in mouse 3T3-L1 cells at 2 uM,Other,17618115.0,
690,300651,3,6,,103226686,446541,Active,,,,,Antagonist activity at pioglitazone-stimulated PPARgamma transcriptional activity in U2OS cells at 1 uM,Other,17618115.0,
691,300652,9,4,,103226686,446541,Unspecified,,,110.0,Kd,Binding affinity to PPARgamma,Confirmatory,17618115.0,
692,300653,3,6,,103226686,446541,Active,,,,,Activation of PPARgamma transcriptional activity in U20S cells at 0.01 to 1 uM,Other,17618115.0,
693,300654,3,4,,103226686,446541,Active,,,,,Stimulation of mouse 3T3-L1 cells differentiation at 2 to 4 uM in presence of guanosine,Other,17618115.0,
694,303351,8,5,,103226686,446541,Active,25014074.0,3614.0,0.033,Ki,Inhibition of human IMPDH type 1,Confirmatory,17958343.0,
695,303352,8,5,,103226686,446541,Active,124419.0,3615.0,0.006999999999999999,Ki,Inhibition of human IMPDH type 2,Confirmatory,17958343.0,
696,303356,6,2,,103226686,446541,Active,,,7.7,IC50,Antiproliferative activity against human K562 cells after 72 hrs,Confirmatory,17958343.0,
697,304371,9,5,,103226686,446541,Active,25014074.0,3614.0,0.04,Ki,Inhibition of human IMPDH 1,Confirmatory,18038969.0,
698,304372,9,5,,103226686,446541,Active,124419.0,3615.0,0.01,Ki,Inhibition of human IMPDH 2,Confirmatory,18038969.0,
699,304373,7,1,,103226686,446541,Inactive,2498443.0,3065.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
700,304373,7,1,,103226686,446541,Inactive,3334210.0,8841.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
701,304373,7,1,,103226686,446541,Inactive,19865267.0,9734.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
702,304373,7,1,,103226686,446541,Inactive,26394832.0,79885.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
703,304373,7,1,,103226686,446541,Inactive,27734403.0,83933.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
704,304373,7,1,,103226686,446541,Inactive,29839394.0,55869.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
705,304373,7,1,,103226686,446541,Inactive,30913097.0,51564.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
706,304373,7,1,,103226686,446541,Inactive,68068066.0,3066.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
707,304373,7,1,,103226686,446541,Inactive,205371758.0,10013.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
708,304373,7,1,,103226686,446541,Inactive,259016348.0,9759.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
709,304373,7,1,,103226686,446541,Inactive,296434519.0,10014.0,,IC50,Inhibition of HDAC,Confirmatory,18038969.0,
710,304374,6,2,,103226686,446541,Active,,,7.7,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTS assay,Confirmatory,18038969.0,
711,304376,3,4,,103226686,446541,Unspecified,,,,,Differentiation of K562 cells at 0.25 uM after 5 days by MTS assay,Other,18038969.0,
712,311524,4,3,,103226686,446541,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
713,328839,3,3,,103226686,446541,Inactive,,,,,Suppression of inclusion formation in zebrafish embryo expressing poly Q102-GFP protein after 24 hrs at 1 uM,Other,17170113.0,
714,328840,3,3,,103226686,446541,Unspecified,,,,,Suppression of aggregation of poly Q102-GFP protein expressed in zebrafish embryo at 1 uM by filter trap assay,Other,17170113.0,
715,331649,6,3,,103226686,446541,Active,,,1.0,IC50,Antiproliferative activity against PDGF-induced rat aortic VSMC by colorimetric assay,Confirmatory,18400498.0,
716,342522,9,5,,103226686,446541,Active,25014074.0,3614.0,,IC50,Inhibition of human IMP dehydrogenase 1,Confirmatory,18583139.0,
717,342523,9,5,,103226686,446541,Active,124419.0,3615.0,,IC50,Inhibition of human IMP dehydrogenase 2,Confirmatory,18583139.0,
718,348818,9,5,,103226686,446541,Active,25014074.0,3614.0,0.04,Ki,Inhibition of human IMPDH1,Confirmatory,18809333.0,
719,348819,9,5,,103226686,446541,Active,124419.0,3615.0,0.01,Ki,Inhibition of human IMPDH2,Confirmatory,18809333.0,
720,348820,6,2,,103226686,446541,Active,,,7.7,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTS assay,Confirmatory,18809333.0,
721,360765,6,2,,103226686,446541,Active,,,5.7,EC50,Antiviral activity against Dengue virus 2 NGC infected in african green monkey Vero cells after 3 days by immunofluorescence assay,Confirmatory,17360676.0,
722,381245,5,3,,103226686,446541,Unspecified,,,,,Antifungal activity against Gibberella zeae IFO 4474 by twofold dilution method,Other,,
723,381247,5,3,,103226686,446541,Unspecified,,,,,Antifungal activity against Alternaria maritima IFO 8618 by twofold dilution method,Other,,
724,392504,6,2,,103226686,446541,Active,,,3.2,IC50,Antiviral activity against Cowpox virus,Confirmatory,19112024.0,
725,409957,3,9,,103226686,446541,Inactive,124028637.0,281293.0,,,Inhibition of bovine liver MAOA,Other,18834112.0,
726,434955,1,2,,47193743,446541,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
727,434959,1,1,,85787933,446541,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
728,434962,1,2,,47193743,446541,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
729,434973,1,3,,47193743,446541,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
730,434989,1,1,,47193743,446541,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
731,435003,1,3,,47193743,446541,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
732,435005,1,1,,47193743,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
733,435022,2,2,,47193743,446541,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
734,435030,1,2,,47193743,446541,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
735,435030,1,2,,47193743,446541,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
736,436272,3,4,,103226686,446541,Inactive,,,,,Antimicrobial activity against Escherichia coli ATCC 35218 by standard disk assay,Other,18991460.0,
737,436273,3,4,,103226686,446541,Inactive,,,,,Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by standard disk assay,Other,18991460.0,
738,436274,3,4,,103226686,446541,Inactive,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by standard disk assay,Other,18991460.0,
739,436275,3,5,,103226686,446541,Inactive,,,,,Antimicrobial activity against Mycobacterium intracellular ATCC 27853 by by alamar blue assay,Other,18991460.0,
740,436276,3,4,,103226686,446541,Inactive,,,,,Antimicrobial activity against Aspergillus fumigatus ATCC 27853 by by standard disk assay,Other,18991460.0,
741,436277,5,2,,103226686,446541,Active,,,8.0,IC50,Antimicrobial activity against Candida albicans ATCC 90028 by by standard disk assay,Confirmatory,18991460.0,
742,436278,5,2,,103226686,446541,Active,,,15.0,IC50,Antimicrobial activity against Cryptococcus neoformans ATCC 90113 by standard disk assay,Confirmatory,18991460.0,
743,436476,5,2,,103226686,446541,Active,,,0.2,CC50,Cytotoxicity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,19482481.0,
744,436477,5,3,,103226686,446541,Active,,,42.0,CC50,Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay,Confirmatory,19482481.0,
745,436478,7,1,,103226686,446541,Unspecified,,,42.0,EC50,Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay,Confirmatory,19482481.0,
746,436479,5,2,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay,Confirmatory,19482481.0,
747,436480,5,2,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay,Confirmatory,19482481.0,
748,436481,5,2,,103226686,446541,Unspecified,,,13.0,CC50,Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining,Confirmatory,19482481.0,
749,436482,5,2,,103226686,446541,Unspecified,,,13.0,EC50,Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay,Confirmatory,19482481.0,
750,436483,5,2,,103226686,446541,Active,,,0.6,EC50,Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay,Confirmatory,19482481.0,
751,436484,5,2,,103226686,446541,Unspecified,,,13.0,EC50,Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay,Confirmatory,19482481.0,
752,436485,5,3,,103226686,446541,Unspecified,,,100.0,CC50,Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay,Confirmatory,19482481.0,
753,436486,5,2,,103226686,446541,Unspecified,,,13.0,EC50,Antiviral activity against Human poliovirus 1 strain Sabin after 2 days by plaque reduction assay,Confirmatory,19482481.0,
754,438029,7,2,,103226686,446541,Unspecified,,,,,Inhibition of Dengue virus IMPDH,Other,19739651.0,
755,449728,1,2,,47193743,446541,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
756,449739,1,2,,47193743,446541,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
757,449746,1,2,,47193743,446541,Inactive,,,,,Single concentration confirmation of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
758,449762,1,2,,47193743,446541,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
759,449763,1,3,,47193743,446541,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
760,449768,1,1,,47193743,446541,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
761,463079,1,2,,47193743,446541,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
762,463082,1,1,,47193743,446541,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
763,463104,1,2,,47193743,446541,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
764,463111,1,1,,47193743,446541,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
765,463141,1,2,,47193743,446541,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
766,463165,1,1,,47193743,446541,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
767,463190,1,2,,47193743,446541,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
768,463195,1,2,,47193743,446541,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
769,463210,1,2,,47193743,446541,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
770,463212,1,1,,47193743,446541,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
771,472783,5,2,,103226686,446541,Active,,,0.2,CC50,Cytotoxicity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,20359898.0,
772,472784,5,3,,103226686,446541,Active,,,42.0,CC50,Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay,Confirmatory,20359898.0,
773,472785,5,3,,103226686,446541,Unspecified,,,100.0,CC50,Cytotoxicity against BHK cells after 48 to 96 hrs by MTT assay,Confirmatory,20359898.0,
774,472786,5,2,,103226686,446541,Unspecified,,,13.0,CC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,20359898.0,
775,472789,5,2,,103226686,446541,Unspecified,,,42.0,EC50,Antiviral activity against Bovine viral diarrhea virus NADL infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method,Confirmatory,20359898.0,
776,472790,5,2,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method,Confirmatory,20359898.0,
777,472791,5,2,,103226686,446541,Unspecified,,,13.0,EC50,Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay,Confirmatory,20359898.0,
778,472792,5,2,,103226686,446541,Unspecified,,,13.0,EC50,Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay,Confirmatory,20359898.0,
779,472793,5,2,,103226686,446541,Unspecified,,,13.0,EC50,Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay,Confirmatory,20359898.0,
780,472794,5,2,,103226686,446541,Active,,,0.6,EC50,Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay,Confirmatory,20359898.0,
781,485270,1,1,,47193743,446541,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
782,485272,1,1,,47193743,446541,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
783,485273,2,1,,47193743,446541,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
784,485275,1,3,,47193743,446541,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
785,485281,1,1,,11112696,446541,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
786,485290,1,1,,11112696,446541,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
787,485290,1,1,,11114111,446541,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
788,485290,1,1,,26747168,446541,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
789,485290,1,1,,26752207,446541,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
790,485290,1,1,,26752208,446541,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
791,485290,1,1,,50104875,446541,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
792,485317,1,2,,47193743,446541,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
793,485346,1,1,,47193743,446541,Active,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
794,485346,1,1,,47193743,446541,Active,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
795,485350,1,2,,92124262,446541,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
796,485350,1,2,,92125597,446541,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
797,488839,1,1,,85148364,446541,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
798,488839,1,1,,85148364,446541,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
799,488847,1,3,,47193743,446541,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
800,488862,1,1,,85148364,446541,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
801,488890,1,2,,47193743,446541,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
802,488895,1,2,,85148364,446541,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
803,488896,1,1,,85148364,446541,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
804,488922,1,2,,47193743,446541,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
805,488965,1,2,,85148364,446541,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
806,488966,1,1,,85148364,446541,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
807,488975,1,2,,47193743,446541,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
808,488977,1,2,,47193743,446541,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
809,489028,1,2,,47193743,446541,Active,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
810,489028,1,2,,47193743,446541,Active,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
811,489030,2,1,,47193743,446541,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
812,489031,2,1,,47193743,446541,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
813,492854,5,2,,103226686,446541,Unspecified,,,62.0,Ki,Inhibition of N-terminal His-tagged Mycobacterium tuberculosis H37Rv IMPDH,Confirmatory,20491506.0,
814,492953,1,1,,85148364,446541,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
815,492956,1,1,,85148364,446541,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
816,492961,1,1,,11112696,446541,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
817,492967,1,2,,92125597,446541,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
818,492967,1,2,,99301234,446541,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
819,492972,1,1,,85148364,446541,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
820,493005,1,1,,47193743,446541,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
821,493008,1,1,,85148364,446541,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
822,493008,1,1,,85148364,446541,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
823,493008,1,1,,85148364,446541,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
824,493008,1,1,,85148364,446541,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
825,493011,1,1,,47193743,446541,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
826,493012,1,1,,47193743,446541,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
827,493033,1,2,,92124262,446541,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
828,493033,1,2,,92125597,446541,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
829,493036,1,2,,47193743,446541,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
830,493087,1,1,,85148364,446541,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
831,493091,1,1,,47193743,446541,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
832,493098,1,1,,47193743,446541,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
833,493131,1,1,,85148364,446541,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
834,493140,1,1,,103914248,446541,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
835,493160,1,1,,47193743,446541,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
836,493162,1,2,,99301234,446541,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
837,493187,1,2,,47193743,446541,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
838,493244,1,1,,85148364,446541,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
839,493244,1,1,,85148364,446541,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
840,493244,1,1,,85148364,446541,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
841,493244,1,1,,85148364,446541,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
842,504326,1,2,,85148364,446541,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
843,504326,1,2,,85148364,446541,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
844,504327,1,1,,11112696,446541,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
845,504329,1,1,,85148364,446541,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
846,504332,1,1,,11112696,446541,Inconclusive,168985070.0,,10.0,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
847,504339,1,1,,47193743,446541,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
848,504357,1,1,,85148364,446541,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
849,504357,1,1,,85148364,446541,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
850,504406,1,1,,47193743,446541,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
851,504408,2,1,,47193743,446541,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
852,504411,1,1,,85148364,446541,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
853,504414,1,1,,85148364,446541,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
854,504414,1,1,,85148364,446541,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
855,504423,1,1,,85148364,446541,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
856,504441,1,1,,85148364,446541,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
857,504444,1,1,,47193743,446541,Inconclusive,224028257.0,4780.0,2.3109,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
858,504454,1,3,,85148364,446541,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
859,504462,1,1,,47193743,446541,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
860,504490,1,2,,85148364,446541,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
861,504523,1,1,,85148364,446541,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
862,504523,1,1,,85148364,446541,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
863,504558,1,1,,85148364,446541,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
864,504577,2,2,,85148364,446541,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
865,504582,2,1,,85148364,446541,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
866,504607,1,1,,47193743,446541,Inactive,,,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,Screening,,
867,504621,1,1,,85148364,446541,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
868,504634,1,1,,85148364,446541,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
869,504648,1,1,,47193743,446541,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
870,504668,1,1,,47193743,446541,Inactive,728984.0,672.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
871,504668,1,1,,47193743,446541,Inactive,116241265.0,580.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
872,504690,1,3,,47193743,446541,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
873,504692,2,2,,85148364,446541,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
874,504700,1,1,,85148364,446541,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
875,504700,1,1,,85148364,446541,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
876,504707,1,1,,85148364,446541,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
877,504707,1,1,,85148364,446541,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
878,504720,1,1,,47193743,446541,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
879,504734,1,1,,85148364,446541,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
880,504749,1,3,,11112696,446541,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
881,504749,1,3,1.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
882,504749,1,3,2.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
883,504749,1,3,3.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
884,504749,1,3,4.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
885,504749,1,3,5.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
886,504749,1,3,6.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
887,504749,1,3,7.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
888,504749,1,3,8.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
889,504749,1,3,9.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
890,504749,1,3,10.0,11112696,446541,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
891,504749,1,3,11.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
892,504749,1,3,12.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
893,504749,1,3,13.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
894,504749,1,3,14.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
895,504749,1,3,15.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
896,504749,1,3,16.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
897,504749,1,3,17.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
898,504749,1,3,18.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
899,504749,1,3,19.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
900,504749,1,3,20.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
901,504749,1,3,21.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
902,504749,1,3,22.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
903,504749,1,3,23.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
904,504749,1,3,24.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
905,504749,1,3,25.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
906,504749,1,3,26.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
907,504749,1,3,27.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
908,504749,1,3,28.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
909,504749,1,3,29.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
910,504749,1,3,30.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
911,504749,1,3,31.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
912,504749,1,3,32.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
913,504749,1,3,33.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
914,504749,1,3,34.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
915,504749,1,3,35.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
916,504749,1,3,36.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
917,504749,1,3,37.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
918,504749,1,3,38.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
919,504749,1,3,39.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
920,504749,1,3,40.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
921,504749,1,3,41.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
922,504749,1,3,42.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
923,504749,1,3,43.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
924,504749,1,3,44.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
925,504749,1,3,45.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
926,504749,1,3,46.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
927,504749,1,3,47.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
928,504749,1,3,48.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
929,504749,1,3,49.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
930,504749,1,3,50.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
931,504749,1,3,51.0,11112696,446541,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
932,504749,1,3,52.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
933,504749,1,3,53.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
934,504749,1,3,54.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
935,504749,1,3,55.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
936,504749,1,3,56.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
937,504749,1,3,57.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
938,504749,1,3,58.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
939,504749,1,3,59.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
940,504749,1,3,60.0,11112696,446541,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
941,504749,1,3,61.0,11112696,446541,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
942,504766,2,1,,85148364,446541,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
943,504770,1,2,,92124262,446541,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
944,504775,1,1,,85148364,446541,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
945,504803,1,1,,85148364,446541,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
946,504832,1,1,,11112696,446541,Active,,,2.5575,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
947,504834,1,1,,11112696,446541,Active,,,1.6137,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
948,504845,1,1,,47193743,446541,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
949,504847,1,1,,11112696,446541,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
950,504847,1,1,,47193743,446541,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
951,504865,1,1,,11112696,446541,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
952,504884,1,2,,85148364,446541,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
953,504891,1,1,,47193743,446541,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
954,504894,1,1,,47193743,446541,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
955,504937,1,2,,47193743,446541,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
956,530141,1,3,,103226686,446541,Unspecified,,,,,Induction of IL-2 expression in mouse dendritic cell co-cultured with Aspergillus fumigatus germ tube at 10 uM after 7 days by RT-PCR,Other,18426895.0,
957,530142,1,3,,103226686,446541,Unspecified,,,,,Induction of TNF-alpha expression in mouse dendritic cell co-cultured with Aspergillus fumigatus germ tube at 10 uM after 7 days by RT-PCR,Other,18426895.0,
958,530143,1,3,,103226686,446541,Unspecified,,,,,Inhibition of Aspergillus fumigatus-mediated dendritic cell maturation assessed as decreased CD86 expression at 10 uM,Other,18426895.0,
959,530144,1,3,,103226686,446541,Unspecified,,,,,Inhibition of Aspergillus fumigatus-mediated dendritic cell maturation assessed as decreased CD83 expression at 10 uM,Other,18426895.0,
960,530145,1,3,,103226686,446541,Unspecified,,,,,Inhibition of Aspergillus fumigatus-mediated dendritic cell maturation assessed as decreased CD40 expression at 10 uM,Other,18426895.0,
961,530146,1,3,,103226686,446541,Unspecified,,,,,Inhibition of Aspergillus fumigatus-mediated dendritic cell maturation assessed as decreased CD1a expression at 10 uM,Other,18426895.0,
962,530147,1,3,,103226686,446541,Unspecified,,,,,Effect on polymorphonuclear neutrophil killing of Aspergillus fumigatus assessed as survival rate of fungi at 10 ug/ml (Rvb = 53% +/- 11%),Other,18426895.0,
963,530148,1,4,,103226686,446541,Unspecified,,,,,Induction of oxidative burst of polymorphonuclear neutrophil co-cultured with Aspergillus fumigatus germlings at 10 uM after 120 minutes relative to untreated control,Other,18426895.0,
964,530149,1,3,,103226686,446541,Unspecified,,,,,Inhibition of Aspergillus fumigatus-mediated dendritic cell maturation assessed as decreased CD80 expression at 10 uM,Other,18426895.0,
965,530151,1,4,,103226686,446541,Unspecified,,,,,Induction of oxidative burst of polymorphonuclear neutrophil co-cultured with Aspergillus fumigatus germlings at 10 uM after 60 minutes relative to untreated control,Other,18426895.0,
966,537733,2,3,,103226686,446541,Inactive,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
967,537734,5,2,,103226686,446541,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
968,537735,2,3,,103226686,446541,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
969,537736,5,2,,103226686,446541,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
970,538353,7,5,,103226686,446541,Active,25014074.0,3614.0,0.019,IC50,Inhibition of human IMPDH1 expressed in Escherichia coli strain BL21(DE3) after 60 mins,Confirmatory,20934342.0,
971,538354,7,5,,103226686,446541,Active,124419.0,3615.0,0.012,IC50,Inhibition of human IMPDH2 expressed in Escherichia coli strain BL21(DE3) after 60 mins,Confirmatory,20934342.0,
972,538355,2,3,,103226686,446541,Unspecified,,,,,Selectivity ratio of IC50 for human IMPDH1 to IC50 for human IMPDH2,Other,20934342.0,
973,538356,4,2,,103226686,446541,Active,,,0.19,IC50,Cytotoxicity against human K562 cells after 72 hrs by trypan blue exclusion assay,Confirmatory,20934342.0,
974,538357,2,4,,103226686,446541,Unspecified,,,,,Selectivity ratio of IC50 for human K562 cells to IC50 for human IMPDH2,Other,20934342.0,
975,538358,1,4,,103226686,446541,Unspecified,,,,,Induction of human K562 cells differentiation assessed as hemoglobin/genomic DNA level at 0.125 uM after 72 hrs relative to untreated control,Other,20934342.0,
976,538359,1,4,,103226686,446541,Unspecified,,,,,Induction of human K562 cells differentiation assessed as hemoglobin/genomic DNA level at 0.25 uM after 72 hrs relative to untreated control,Other,20934342.0,
977,538360,1,4,,103226686,446541,Unspecified,,,,,Induction of human K562 cells differentiation assessed as hemoglobin/genomic DNA level at 0.5 uM after 72 hrs relative to untreated control,Other,20934342.0,
978,538361,1,4,,103226686,446541,Unspecified,,,,,Induction of human K562 cells differentiation assessed as hemoglobin/genomic DNA level at 1 uM after 72 hrs relative to untreated control,Other,20934342.0,
979,538362,1,4,,103226686,446541,Unspecified,,,,,Induction of human K562 cells differentiation assessed as hemoglobin/genomic DNA level at 2 uM after 72 hrs relative to untreated control,Other,20934342.0,
980,538363,1,4,,103226686,446541,Unspecified,,,,,Induction of human K562 cells differentiation assessed as hemoglobin/genomic DNA level at 4 uM after 72 hrs relative to untreated control,Other,20934342.0,
981,540253,1,1,,47193743,446541,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
982,540253,1,1,,47193743,446541,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
983,540253,1,1,,47193743,446541,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
984,540263,1,1,,47193743,446541,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
985,540263,1,1,,47193743,446541,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
986,540267,1,1,,47193743,446541,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
987,540295,1,1,,85148364,446541,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
988,540299,1,2,,92124262,446541,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
989,540299,1,2,,92125597,446541,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
990,540303,1,1,,47193743,446541,Inconclusive,6679377.0,18792.0,0.3162,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
991,540303,1,1,,47193743,446541,Inconclusive,7242179.0,18793.0,0.3162,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
992,540303,1,1,,47193743,446541,Inconclusive,257471003.0,18815.0,0.3162,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
993,540308,1,1,,85148364,446541,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
994,540317,1,1,,47193743,446541,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
995,540336,1,1,,85148364,446541,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
996,540336,1,1,,85148364,446541,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
997,540364,1,2,,85148364,446541,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
998,580126,6,5,,103226686,446541,Active,124419.0,3615.0,0.006999999999999999,Ki,Inhibition of human IMPDH2 by Spectrophotometer,Confirmatory,21324702.0,
999,580127,4,2,,103226686,446541,Active,,,7.7,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTS assay,Confirmatory,21324702.0,
1000,580128,6,5,,103226686,446541,Active,25014074.0,3614.0,0.033,Ki,Inhibition of human IMPDH1 by Spectrophotometry,Confirmatory,21324702.0,
1001,588211,2,3,,103226686,446541,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1002,588212,2,3,,103226686,446541,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1003,588213,2,3,,103226686,446541,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1004,588214,2,3,,103226686,446541,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1005,588215,2,3,,103226686,446541,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1006,588216,2,3,,103226686,446541,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1007,588217,2,3,,103226686,446541,Active,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1008,588218,2,3,,103226686,446541,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1009,588219,2,3,,103226686,446541,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1010,588335,1,1,,85148364,446541,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1011,588352,1,2,,85148364,446541,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1012,588354,1,1,,85148364,446541,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1013,588358,1,2,,85148364,446541,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1014,588379,1,2,,124882524,446541,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
1015,588379,1,2,,124882528,446541,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
1016,588405,1,1,,85148364,446541,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1017,588413,1,2,,47193743,446541,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1018,588436,1,1,,85148364,446541,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1019,588453,1,1,,47193743,446541,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1020,588456,1,1,,47193743,446541,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1021,588458,1,1,,85148364,446541,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1022,588473,1,1,,47193743,446541,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1023,588473,1,1,,47193743,446541,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1024,588475,1,2,,47193743,446541,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1025,588475,1,2,,47193743,446541,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1026,588478,1,2,,124812223,446541,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1027,588489,1,1,,85148364,446541,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1028,588492,1,1,,85148364,446541,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1029,588493,1,2,,85148364,446541,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1030,588497,1,2,,85148364,446541,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1031,588497,1,2,,85148364,446541,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1032,588497,1,2,,85148364,446541,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1033,588499,1,3,,85148364,446541,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1034,588499,1,3,,85148364,446541,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1035,588499,1,3,,85148364,446541,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1036,588501,1,2,,85148364,446541,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1037,588501,1,2,,85148364,446541,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1038,588501,1,2,,85148364,446541,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1039,588511,1,2,,47193743,446541,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1040,588519,1,2,,92124262,446541,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1041,588519,1,2,,92125597,446541,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1042,588549,1,1,,85148364,446541,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1043,588579,1,1,,11112696,446541,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1044,588579,1,1,,47193743,446541,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1045,588579,1,1,,124882524,446541,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1046,588579,1,1,,124882525,446541,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1047,588579,1,1,,124882528,446541,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1048,588579,1,1,,124882529,446541,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1049,588579,1,1,,124882530,446541,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1050,588590,1,1,,47193743,446541,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1051,588591,1,1,,47193743,446541,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1052,588621,1,1,,85148364,446541,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1053,588627,1,1,,47193743,446541,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1054,588664,1,2,,85148364,446541,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1055,588664,1,2,,85148364,446541,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1056,588674,1,2,,85148364,446541,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1057,588675,1,1,,47193743,446541,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1058,588676,1,1,,47193743,446541,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1059,588689,1,1,,85148364,446541,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1060,588692,2,1,,85148364,446541,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1061,588719,1,2,,85148364,446541,Active,,,9.68,CC50,Vero 76 Cytoxicity Assay for VEEV Compounds,Confirmatory,,
1062,588726,1,2,,85148364,446541,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1063,588727,1,1,,85148364,446541,Active,,,0.05,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1064,588795,1,1,,47193743,446541,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1065,588814,1,3,,85148364,446541,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1066,588819,1,4,,85148364,446541,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1067,588832,1,1,,85148364,446541,Inactive,7300964.0,,,,Hedgehog Measured in Biochemical System Using Plate Reader - 2070-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1068,588834,2,1,,144204161,446541,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1069,588850,1,1,,85148364,446541,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1070,588852,1,3,,85148364,446541,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1071,588855,1,1,,47193743,446541,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1072,588856,1,1,,47193743,446541,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1073,589072,1,10,,103226686,446541,Unspecified,30173486.0,54577.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A7,Other,,
1074,589073,1,10,,103226686,446541,Unspecified,29839637.0,54576.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A8,Other,,
1075,589075,1,10,,103226686,446541,Unspecified,29839636.0,54575.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A10,Other,,
1076,602123,1,1,,85148364,446541,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1077,602141,1,1,,85148364,446541,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1078,602162,1,1,,85148364,446541,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1079,602163,1,1,,85148364,446541,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1080,602179,1,2,,47193743,446541,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1081,602229,1,1,,85148364,446541,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1082,602233,1,1,,47193743,446541,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1083,602244,1,2,,85148364,446541,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1084,602247,1,2,,85148364,446541,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1085,602248,1,2,,85148364,446541,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1086,602250,1,2,,85148364,446541,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1087,602252,1,1,,85148364,446541,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1088,602252,1,1,,85148364,446541,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1089,602261,1,1,,85148364,446541,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1090,602274,1,2,,85148364,446541,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1091,602281,1,1,,85148364,446541,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1092,602281,1,1,,85148364,446541,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1093,602310,1,2,,47193743,446541,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1094,602313,1,1,,47193743,446541,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1095,602314,1,2,,92124262,446541,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1096,602314,1,2,,92125597,446541,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1097,602329,1,1,,85148364,446541,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1098,602332,1,1,,11112696,446541,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1099,602332,1,1,,47193743,446541,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1100,602332,1,1,,124882524,446541,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1101,602332,1,1,,124882525,446541,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1102,602332,1,1,,124882528,446541,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1103,602332,1,1,,124882529,446541,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1104,602332,1,1,,124882530,446541,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1105,602340,1,2,,85148364,446541,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1106,602342,2,1,,85148364,446541,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1107,602346,1,1,,85148364,446541,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1108,602363,1,1,,85148364,446541,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1109,602393,1,1,,85148364,446541,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1110,602396,1,2,,85148364,446541,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1111,602399,1,2,,85148364,446541,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1112,602405,1,1,,85148364,446541,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1113,602410,1,1,,85148364,446541,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1114,602429,1,1,,85148364,446541,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1115,602438,1,1,,85148364,446541,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1116,602440,1,1,,85148364,446541,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1117,602449,1,2,,85148364,446541,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1118,602481,1,1,,85148364,446541,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1119,623870,1,1,,85148364,446541,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1120,623870,1,1,,85148364,446541,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1121,623877,1,1,,85148364,446541,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1122,623901,1,1,,85148364,446541,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1123,624030,1,2,,11112696,446541,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1124,624031,1,2,,11112696,446541,Inconclusive,,,12.2898,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1125,624032,1,2,,11112696,446541,Active,8393992.0,24660.0,0.9762,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1126,624037,1,3,,85148364,446541,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1127,624038,1,3,,85148364,446541,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1128,624040,1,3,,85148364,446541,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1129,624044,1,2,,11112696,446541,Inconclusive,8393992.0,24660.0,6.0012,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1130,624125,1,4,,85148364,446541,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1131,624126,1,3,,85148364,446541,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1132,624127,1,2,,85148364,446541,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1133,624156,1,1,,85787933,446541,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1134,624168,1,1,,85148364,446541,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1135,624169,1,1,,85148364,446541,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1136,624170,1,1,,11112696,446541,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1137,624170,1,1,,47193743,446541,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1138,624171,1,1,,47193743,446541,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1139,624172,1,1,,11112696,446541,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1140,624172,1,1,,47193743,446541,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1141,624173,1,3,,11112696,446541,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1142,624173,1,3,,47193743,446541,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1143,624178,1,1,,47193743,446541,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1144,624202,1,1,,47193743,446541,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1145,624204,1,2,,85148364,446541,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1146,624246,1,1,,47193743,446541,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1147,624256,1,2,,85148364,446541,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1148,624263,1,1,,47193743,446541,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1149,624263,1,1,,47193743,446541,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1150,624267,1,2,,85148364,446541,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1151,624267,1,2,,85148364,446541,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1152,624268,1,3,,85148364,446541,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1153,624288,1,1,,47193743,446541,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1154,624291,1,1,,47193743,446541,Inactive,121312.0,1081.0,,Potency,qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy,Confirmatory,,
1155,624296,1,1,,11112696,446541,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1156,624296,1,1,,47193743,446541,Inactive,7705682.0,51053.0,0.3663,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1157,624297,1,1,,11112696,446541,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1158,624297,1,1,,47193743,446541,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1159,624304,1,2,,85148364,446541,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1160,624330,1,2,,85148364,446541,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1161,624349,1,2,,92124262,446541,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1162,624349,1,2,,92125597,446541,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1163,624349,1,2,,92307652,446541,Active,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1164,624349,1,2,,92308693,446541,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1165,624349,1,2,,121363268,446541,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1166,624352,1,1,,85148364,446541,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1167,624354,1,1,,85148364,446541,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1168,624377,1,1,,85148364,446541,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1169,624416,1,1,,85148364,446541,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1170,624417,1,1,,47193743,446541,Inconclusive,1724069.0,2740.0,0.8913,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1171,624418,1,1,,47193743,446541,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1172,624463,1,1,,47193743,446541,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1173,624464,1,1,,47193743,446541,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1174,624465,1,1,,47193743,446541,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1175,624466,1,3,,85148364,446541,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1176,624467,1,1,,85148364,446541,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1177,624483,1,1,,85148364,446541,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1178,624611,1,9,,103226686,446541,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
1179,624613,1,9,,103226686,446541,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
1180,624630,3,7,,103226686,446541,Unspecified,136729.0,54658.0,185.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A1,Confirmatory,15781124.0,
1181,624631,3,7,,103226686,446541,Unspecified,29839636.0,54575.0,119.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A10,Confirmatory,15781124.0,
1182,624635,3,7,,103226686,446541,Unspecified,30173486.0,54577.0,,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A7,Confirmatory,15781124.0,
1183,624636,3,7,,103226686,446541,Unspecified,29839637.0,54576.0,,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A8,Confirmatory,15781124.0,
1184,624637,3,7,,103226686,446541,Unspecified,29839451.0,54600.0,291.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A9,Confirmatory,15781124.0,
1185,625144,5,5,,103226686,446541,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1186,625145,4,7,,103226686,446541,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1187,625146,5,5,,103226686,446541,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1188,625147,4,7,,103226686,446541,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1189,625148,4,7,,103226686,446541,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1190,625149,4,7,,103226686,446541,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1191,625150,5,5,,103226686,446541,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1192,625151,4,7,,103226686,446541,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1193,625152,4,7,,103226686,446541,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1194,625153,4,7,,103226686,446541,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1195,625154,4,7,,103226686,446541,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1196,625155,4,7,,103226686,446541,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1197,625156,1,9,,103226686,446541,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1198,625157,6,2,,103226686,446541,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1199,625158,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1200,625159,5,5,,103226686,446541,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1201,625160,1,9,,103226686,446541,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1202,625161,4,7,,103226686,446541,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1203,625162,4,7,,103226686,446541,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1204,625163,4,7,,103226686,446541,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1205,625164,1,6,,103226686,446541,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1206,625165,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1207,625166,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1208,625167,5,5,,103226686,446541,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1209,625168,4,7,,103226686,446541,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1210,625169,1,6,,103226686,446541,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1211,625170,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1212,625171,4,7,,103226686,446541,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1213,625172,4,7,,103226686,446541,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1214,625173,5,5,,103226686,446541,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1215,625174,5,5,,103226686,446541,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1216,625175,5,5,,103226686,446541,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1217,625176,1,9,,103226686,446541,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1218,625177,5,5,,103226686,446541,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1219,625178,5,5,,103226686,446541,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1220,625179,1,9,,103226686,446541,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1221,625180,5,5,,103226686,446541,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1222,625181,5,5,,103226686,446541,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1223,625182,5,5,,103226686,446541,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1224,625183,5,5,,103226686,446541,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1225,625184,5,5,,103226686,446541,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1226,625185,5,5,,103226686,446541,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1227,625186,5,5,,103226686,446541,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1228,625187,5,5,,103226686,446541,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1229,625188,1,9,,103226686,446541,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1230,625189,1,7,,103226686,446541,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1231,625190,4,5,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1232,625191,4,7,,103226686,446541,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1233,625192,4,7,,103226686,446541,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1234,625193,5,5,,103226686,446541,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1235,625194,4,7,,103226686,446541,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1236,625195,4,7,,103226686,446541,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1237,625196,5,6,,103226686,446541,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1238,625197,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1239,625198,4,7,,103226686,446541,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1240,625199,4,7,,103226686,446541,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1241,625200,4,7,,103226686,446541,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1242,625201,4,7,,103226686,446541,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1243,625202,4,7,,103226686,446541,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1244,625203,4,7,,103226686,446541,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1245,625204,4,7,,103226686,446541,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1246,625205,4,7,,103226686,446541,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1247,625206,4,7,,103226686,446541,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1248,625207,4,7,,103226686,446541,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1249,625208,5,5,,103226686,446541,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1250,625209,4,7,,103226686,446541,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1251,625210,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1252,625211,1,6,,103226686,446541,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1253,625212,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1254,625213,4,7,,103226686,446541,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1255,625214,1,9,,103226686,446541,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1256,625215,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1257,625216,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1258,625217,4,7,,103226686,446541,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1259,625218,4,7,,103226686,446541,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1260,625219,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1261,625220,4,7,,103226686,446541,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1262,625221,4,7,,103226686,446541,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1263,625222,4,7,,103226686,446541,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1264,625223,4,7,,103226686,446541,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1265,625224,3,4,,103226686,446541,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1266,625225,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1267,625226,4,7,,103226686,446541,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1268,625227,4,7,,103226686,446541,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1269,625228,4,7,,103226686,446541,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1270,625229,5,5,,103226686,446541,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1271,625230,1,6,,103226686,446541,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1272,625231,4,7,,103226686,446541,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1273,625232,1,9,,103226686,446541,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1274,625233,4,7,,103226686,446541,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1275,625234,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1276,625235,4,7,,103226686,446541,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1277,625236,5,5,,103226686,446541,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1278,625237,4,7,,103226686,446541,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1279,625238,4,7,,103226686,446541,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1280,625239,4,7,,103226686,446541,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1281,625240,1,9,,103226686,446541,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1282,625241,4,7,,103226686,446541,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1283,625242,4,7,,103226686,446541,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1284,625243,5,5,,103226686,446541,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1285,625244,5,5,,103226686,446541,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1286,625245,5,5,,103226686,446541,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1287,625246,1,9,,103226686,446541,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1288,625247,5,5,,103226686,446541,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1289,625248,5,5,,103226686,446541,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1290,625249,5,5,,103226686,446541,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1291,625250,5,5,,103226686,446541,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1292,625251,5,5,,103226686,446541,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1293,625252,4,7,,103226686,446541,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1294,625253,4,7,,103226686,446541,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1295,625254,4,7,,103226686,446541,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1296,625255,4,7,,103226686,446541,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1297,625256,4,7,,103226686,446541,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1298,625257,4,7,,103226686,446541,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1299,625258,4,7,,103226686,446541,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1300,625259,4,7,,103226686,446541,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1301,625260,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1302,625261,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1303,625262,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1304,625263,4,7,,103226686,446541,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1305,625264,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1306,625265,1,6,,103226686,446541,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1307,625266,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1308,625267,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1309,625268,4,2,,103226686,446541,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1310,625268,4,2,,103226686,446541,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1311,625268,4,2,,103226686,446541,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1312,625268,4,2,,103226686,446541,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1313,625269,4,7,,103226686,446541,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1314,625270,4,7,,103226686,446541,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1315,625271,5,5,,103226686,446541,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1316,625272,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1317,625273,4,6,,103226686,446541,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1318,625274,1,6,,103226686,446541,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1319,625275,3,4,,103226686,446541,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1320,625279,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1321,625280,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1322,625281,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1323,625282,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1324,625283,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1325,625284,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1326,625285,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1327,625286,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1328,625287,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1329,625288,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1330,625289,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1331,625290,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1332,625291,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1333,625292,1,3,,103226686,446541,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1334,637675,3,2,,103226686,446541,Active,,,0.28,IC50,Immunosuppressive activity in in mouse T-cells assessed as inhibition of concanavalin A-induced proliferation,Confirmatory,22172700.0,
1335,637676,5,2,,103226686,446541,Active,,,1.5,IC50,Inhibition of IMPDH2,Confirmatory,22172700.0,
1336,642215,3,2,,103226686,446541,Unspecified,,,12.5,CC50,Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining,Confirmatory,22047799.0,
1337,642283,3,2,,103226686,446541,Active,,,1.5,EC50,Antiviral activity against Vaccinia virus Lister Elstree infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining,Confirmatory,22047799.0,
1338,651550,1,1,,47193743,446541,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1339,651560,1,1,,85148364,446541,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1340,651572,1,2,,85148364,446541,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1341,651602,1,1,,85148364,446541,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1342,651602,1,1,,85148364,446541,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1343,651602,1,1,,85148364,446541,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1344,651631,4,1,,144204161,446541,Active,269849759.0,7157.0,0.0717,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1345,651632,4,1,,144204161,446541,Inactive,296439460.0,79915.0,9.0226,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1346,651633,4,1,,144204161,446541,Inconclusive,,,0.40299999999999997,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1347,651634,4,1,,144204161,446541,Active,,,0.20199999999999999,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1348,651635,1,3,,47193743,446541,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1349,651636,1,1,,85148364,446541,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1350,651640,1,1,,85148364,446541,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1351,651644,1,1,,47193743,446541,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1352,651647,1,1,,85148364,446541,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1353,651654,1,1,,85148364,446541,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1354,651658,1,1,,85148364,446541,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1355,651661,2,1,,85148364,446541,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1356,651687,1,1,,85148364,446541,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1357,651699,1,1,,85148364,446541,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1358,651699,1,1,,85148364,446541,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1359,651702,1,2,,85148364,446541,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1360,651704,2,1,,85148364,446541,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1361,651710,1,1,,85148364,446541,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1362,651711,2,1,,85148364,446541,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1363,651718,1,2,,85148364,446541,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1364,651719,1,2,,85148364,446541,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1365,651723,1,1,,85148364,446541,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1366,651724,1,1,,47193743,446541,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1367,651725,1,1,,47193743,446541,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1368,651768,1,2,,47193743,446541,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1369,651800,1,1,,85148364,446541,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1370,651819,1,1,,47193743,446541,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1371,651820,1,1,,47193743,446541,Active,,,1.9953,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1372,651821,2,4,,85148364,446541,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1373,651828,1,2,,92308693,446541,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1374,651957,1,1,,85148364,446541,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1375,651958,1,1,,85148364,446541,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1376,651965,1,1,,47193743,446541,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1377,651999,1,1,,85148364,446541,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1378,652010,1,1,,85148364,446541,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1379,652017,1,1,,85148364,446541,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1380,652025,1,1,,47193743,446541,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1381,652039,1,1,,85148364,446541,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1382,652048,1,2,,47193743,446541,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1383,652048,1,2,,144204161,446541,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1384,652051,1,1,,47193743,446541,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1385,652051,1,1,,144204161,446541,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1386,652054,1,1,,47193743,446541,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1387,652067,1,4,,85148364,446541,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1388,652104,1,1,,47193743,446541,Inconclusive,20140568.0,23435.0,35.4813,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1389,652105,1,1,,47193743,446541,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1390,652106,1,1,,47193743,446541,Active,586067.0,6622.0,7.0795,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1391,652115,1,1,,85148364,446541,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1392,652126,1,3,,85148364,446541,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1393,652162,2,1,,85148364,446541,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1394,652163,1,1,,85148364,446541,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1395,652197,1,1,,85148364,446541,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1396,652257,1,1,,85148364,446541,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1397,657090,4,2,,103226686,446541,Active,,,0.63,IC50,Inhibition of IMPDH2 using inosine 5'-monophosphate as substrate by spectrophotometry,Confirmatory,22464133.0,
1398,657091,2,3,,103226686,446541,Active,,,0.32,IC50,Immunosuppressive activity in C57BL/6 mouse T lymphocytes assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,22464133.0,
1399,663911,2,2,,103226686,446541,Unspecified,,,12.5,CC50,Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay,Confirmatory,22513121.0,
1400,664263,2,2,,103226686,446541,Active,,,1.5,EC50,Antiviral activity against Vaccinia virus Elstree-Lister ATCC VR-1549 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining,Confirmatory,22513121.0,
1401,668549,2,3,,103226686,446541,Active,,,0.193,IC50,Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay,Confirmatory,22621840.0,
1402,668550,2,3,,103226686,446541,Active,,,0.075,IC50,Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay,Confirmatory,22621840.0,
1403,668551,2,3,,103226686,446541,Unspecified,,,156.0,IC50,Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay,Confirmatory,22621840.0,
1404,668552,2,3,,103226686,446541,Active,,,9.76,IC50,Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,22621840.0,
1405,668553,2,3,,103226686,446541,Active,,,2.18,IC50,Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay,Confirmatory,22621840.0,
1406,668554,2,3,,103226686,446541,Active,,,1.28,IC50,Antiproliferative activity against activated-human PBMC after 96 hrs by MTT assay,Confirmatory,22621840.0,
1407,676607,1,4,,103226686,446541,Unspecified,,,,,Growth restoration activity in cdc2-1 rad9-deficient Saccharomyces cerevisiae assessed as growth zone at 0.05 ug/disc incubated at 37 degC for 6 hrs and 28 degC for 2 days,Other,22575162.0,
1408,685500,2,2,,103226686,446541,Unspecified,,,100.0,IC50,HARVARD: Cytotoxicity in HepG2 cell line,Confirmatory,22586124.0,
1409,685501,2,2,,103226686,446541,Active,,,1.0,IC50,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,Confirmatory,22586124.0,
1410,685503,2,2,,103226686,446541,Unspecified,,,5.0,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection,Confirmatory,22586124.0,
1411,686940,1,1,,85148364,446541,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1412,686964,1,1,,85148364,446541,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1413,686970,1,2,,47193743,446541,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1414,686971,1,2,,47193743,446541,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1415,686977,2,1,,49698550,446541,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1416,686978,1,1,,47193743,446541,Active,79154014.0,55775.0,0.1836,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1417,686978,1,1,,124882524,446541,Active,79154014.0,55775.0,0.1496,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1418,686978,1,1,,124882525,446541,Active,79154014.0,55775.0,0.3663,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1419,686978,1,1,,124882528,446541,Active,79154014.0,55775.0,0.3759,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1420,686978,1,1,,144204161,446541,Active,79154014.0,55775.0,0.1137,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1421,686979,1,1,,47193743,446541,Active,79154014.0,55775.0,0.0326,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1422,686979,1,1,,124882524,446541,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1423,686979,1,1,,124882525,446541,Active,79154014.0,55775.0,0.5805,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1424,686979,1,1,,124882528,446541,Active,79154014.0,55775.0,0.2986,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1425,686979,1,1,,144204161,446541,Active,79154014.0,55775.0,0.1137,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1426,686996,1,1,,85148364,446541,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1427,687014,1,1,,85148364,446541,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1428,687016,1,1,,85148364,446541,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1429,697852,1,7,,103226686,446541,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1430,697853,1,7,,103226686,446541,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
1431,699264,1,2,,103226686,446541,Unspecified,,,,,"Selectivity index, ratio of CC50 for BHK cells to IC50 for Dengue virus 2 infected in BHK-D2RepT cells",Other,22742496.0,
1432,699265,2,3,,103226686,446541,Active,,,1.9,CC50,Cytotoxicity against BHK cells incubated for 48 hrs by MTT assay,Confirmatory,22742496.0,
1433,699266,2,2,,103226686,446541,Active,,,0.7,IC50,Antiviral activity against Dengue virus 2 infected in BHK-D2RepT cells assessed as reduction in viral replication incubated for 48 hrs by luciferase reporter replicon-based assay,Confirmatory,22742496.0,
1434,705460,1,2,,103226686,446541,Active,,,,,Antiapicomplexan activity against Toxoplasma gondii THdhxgTRP tachyzoites harboring insertional mutation assessed as growth inhibition after 6 weeks,Other,22970937.0,
1435,720504,1,1,,47193743,446541,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1436,720508,1,1,,85148364,446541,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1437,720509,1,1,,85148364,446541,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1438,720511,1,1,,85148364,446541,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1439,720516,2,1,,144204161,446541,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1440,720532,1,1,,124882524,446541,Active,420597.0,,0.3981,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1441,720532,1,1,,124882525,446541,Active,420597.0,,1.4125,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1442,720532,1,1,,124882528,446541,Inconclusive,420597.0,,1.0,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1443,720532,1,1,,124882529,446541,Active,420597.0,,1.2589,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1444,720532,1,1,,124882530,446541,Inconclusive,420597.0,,100.0,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1445,720532,1,1,,144204161,446541,Active,420597.0,,0.8913,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1446,720533,1,1,,124882524,446541,Active,,,1.0,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1447,720533,1,1,,124882525,446541,Active,,,1.4125,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1448,720533,1,1,,124882528,446541,Active,,,1.0,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1449,720533,1,1,,124882529,446541,Active,,,1.4125,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1450,720533,1,1,,124882530,446541,Active,,,0.3981,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1451,720533,1,1,,144204161,446541,Active,,,0.8913,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1452,720542,1,2,,47193743,446541,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1453,720543,1,1,,85148364,446541,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1454,720551,1,2,,47193743,446541,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1455,720552,2,1,,144204161,446541,Active,269849759.0,7157.0,0.06766,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1456,720553,1,2,,47193743,446541,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1457,720579,2,1,,47193743,446541,Active,222762.0,3707576.0,4.4668,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1458,720579,2,1,,124882525,446541,Active,222762.0,3707576.0,5.6234,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1459,720580,1,1,,47193743,446541,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1460,720580,1,1,,124882525,446541,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1461,720582,1,1,,85148364,446541,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1462,720596,1,1,,85148364,446541,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1463,720634,2,1,,144204161,446541,Inactive,,,0.0639,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1464,720635,2,1,,144204161,446541,Inconclusive,,,5.6929,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1465,720637,2,1,,144204161,446541,Inconclusive,,,6.766,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1466,720641,1,2,,92307652,446541,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1467,720641,1,2,,92308693,446541,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1468,720647,1,2,,85148364,446541,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1469,720648,1,1,,85148364,446541,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1470,720674,2,2,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1471,720675,2,2,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1472,720678,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1473,720679,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1474,720680,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1475,720681,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1476,720682,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1477,720683,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1478,720684,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1479,720685,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1480,720686,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1481,720687,2,2,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1482,720691,4,1,,144204161,446541,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1483,720692,3,1,,144204161,446541,Inconclusive,311348376.0,2908.0,0.1285,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1484,720693,3,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1485,720700,1,4,,85148364,446541,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1486,720702,1,1,,85148364,446541,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1487,720704,1,4,,85148364,446541,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1488,720706,1,2,,85148364,446541,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1489,720707,1,2,,47193743,446541,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1490,720708,1,2,,47193743,446541,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1491,720709,1,2,,47193743,446541,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1492,720711,1,2,,47193743,446541,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1493,720717,1,3,,92124262,446541,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1494,720717,1,3,,92125597,446541,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1495,720717,1,3,,92307652,446541,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1496,720717,1,3,,92308693,446541,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1497,720719,2,1,,144204161,446541,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1498,720725,2,1,,144204161,446541,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1499,743012,3,1,,144204161,446541,Active,,,0.1604,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1500,743014,3,1,,144204161,446541,Active,,,0.1604,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1501,743015,3,1,,144204161,446541,Active,,,0.20199999999999999,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1502,743033,3,1,,144204161,446541,Inconclusive,,,0.2286,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1503,743035,2,1,,144204161,446541,Active,124375976.0,367.0,0.4065,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1504,743036,2,1,,144204161,446541,Active,124375976.0,367.0,0.9099,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1505,743040,3,1,,144204161,446541,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1506,743041,3,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1507,743042,3,1,,144204161,446541,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1508,743053,2,1,,144204161,446541,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1509,743054,2,1,,144204161,446541,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1510,743063,2,1,,144204161,446541,Inconclusive,124375976.0,367.0,0.287746,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1511,743064,3,1,,144204161,446541,Active,,,0.7167,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1512,743065,3,1,,144204161,446541,Active,399498506.0,24831.0,0.5074,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1513,743066,3,1,,144204161,446541,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1514,743067,2,1,,144204161,446541,Inconclusive,399498506.0,24831.0,0.507379,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1515,743069,2,1,,144204161,446541,Active,348019627.0,2099.0,0.5117,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1516,743074,2,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1517,743075,2,1,,144204161,446541,Inconclusive,348019627.0,2099.0,0.1021,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1518,743077,2,1,,144204161,446541,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1519,743078,2,1,,144204161,446541,Active,348019627.0,2099.0,0.09825210000000001,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1520,743079,3,1,,144204161,446541,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1521,743080,3,1,,144204161,446541,Inconclusive,348019627.0,2099.0,0.9023,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1522,743081,3,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1523,743083,3,1,,144204161,446541,Inactive,119597822.0,1588.0,0.2266,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1524,743084,3,1,,144204161,446541,Inconclusive,,,5.6929,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1525,743085,3,1,,144204161,446541,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1526,743086,3,1,,144204161,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1527,743091,2,1,,144204161,446541,Inconclusive,348019627.0,2099.0,0.9022610000000001,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1528,743094,3,1,,144204161,446541,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1529,743122,2,1,,144204161,446541,Inconclusive,51095037.0,196.0,12.7448,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1530,743126,1,1,,85148364,446541,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1531,743139,2,1,,144204161,446541,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1532,743140,2,1,,144204161,446541,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1533,743191,3,1,,170465182,446541,Active,216409692.0,5468.0,0.473,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1534,743194,3,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1535,743199,2,1,,170465182,446541,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1536,743202,4,1,,170465182,446541,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1537,743203,3,1,,170465182,446541,Inconclusive,,,1.8832,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1538,743209,3,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1539,743210,4,1,,170465182,446541,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1540,743211,3,1,,170465182,446541,Inconclusive,,,1.8832,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1541,743212,3,1,,170465182,446541,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1542,743213,3,1,,170465182,446541,Inconclusive,,,0.7497,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1543,743215,3,1,,170465182,446541,Inconclusive,216409690.0,5467.0,14.9589,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1544,743217,3,1,,170465182,446541,Inconclusive,325495553.0,9971.0,0.7497,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1545,743218,3,1,,170465182,446541,Inconclusive,,,0.4216,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1546,743219,3,1,,170465182,446541,Inconclusive,20149576.0,4780.0,0.5622119999999999,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1547,743220,3,1,,170465182,446541,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1548,743221,3,1,,170465182,446541,Inconclusive,,,0.9438,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1549,743222,3,1,,170465182,446541,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1550,743223,3,1,,170465182,446541,Inconclusive,216409708.0,7421.0,0.4253,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1551,743224,3,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1552,743225,3,1,,170465182,446541,Inconclusive,,,0.6007,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1553,743226,2,1,,170465182,446541,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1554,743227,2,1,,170465182,446541,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1555,743228,3,1,,170465182,446541,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1556,743239,2,1,,170465182,446541,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1557,743240,2,1,,170465182,446541,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1558,743241,2,1,,170465182,446541,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1559,743242,2,1,,170465182,446541,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1560,743244,1,1,,144204161,446541,Inactive,,,2.5119,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1561,743255,1,1,,47193743,446541,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1562,743266,1,2,,47193743,446541,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1563,743269,1,1,,85148364,446541,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1564,743269,1,1,,85148364,446541,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1565,743279,1,2,,47193743,446541,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1566,743287,1,1,,85148364,446541,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1567,743398,1,1,,85148364,446541,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1568,767473,1,1,,103226686,446541,Inactive,,,,,Induction of human K562 cell differentiation at 1 uM after 72 hrs by trypan blue exclusion assay in presence of guanosine,Other,23937979.0,
1569,767479,1,1,,103226686,446541,Inactive,,,,,Antiproliferative activity against human K562 cells at 1 uM in presence of guanosine,Other,23937979.0,
1570,767480,1,2,,103226686,446541,Unspecified,2498443.0,3065.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1571,767480,1,2,,103226686,446541,Unspecified,3334210.0,8841.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1572,767480,1,2,,103226686,446541,Unspecified,19865267.0,9734.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1573,767480,1,2,,103226686,446541,Unspecified,26394832.0,79885.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1574,767480,1,2,,103226686,446541,Unspecified,27734403.0,83933.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1575,767480,1,2,,103226686,446541,Unspecified,29839394.0,55869.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1576,767480,1,2,,103226686,446541,Unspecified,30913097.0,51564.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1577,767480,1,2,,103226686,446541,Unspecified,68068066.0,3066.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1578,767480,1,2,,103226686,446541,Unspecified,205371758.0,10013.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1579,767480,1,2,,103226686,446541,Unspecified,259016348.0,9759.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1580,767480,1,2,,103226686,446541,Unspecified,296434519.0,10014.0,,,Inhibition of HDAC in human K562 cells using Boc-Lys[Ac]-AMC as substrate at 10 uM incubated for 10 mins prior to substrate addition measured after 80 mins by fluorescence assay,Other,23937979.0,
1581,767486,1,1,,103226686,446541,Active,,,,,Antiproliferative activity against human K562 cells at 1 uM,Other,23937979.0,
1582,774863,1,2,,103226686,446541,Unspecified,,,100.0,CC50,Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay,Confirmatory,23999140.0,
1583,774864,1,1,,103226686,446541,Active,,,4.16,IC50,Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis,Confirmatory,23999140.0,
1584,774865,1,1,,103226686,446541,Unspecified,,,,,"Selectivity index, ratio of CC50 for human Huh7.5 cells to IC50 for HCV expressing pFL-J6/JFH/JC1",Other,23999140.0,
1585,774866,1,1,,103226686,446541,Unspecified,,,624.34,CC50,Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay,Confirmatory,23999140.0,
1586,774867,1,1,,103226686,446541,Active,,,10.15,IC50,Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs,Confirmatory,23999140.0,
1587,774868,1,1,,103226686,446541,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Nancy",Other,23999140.0,
1588,774869,1,1,,103226686,446541,Unspecified,,,69.36,IC50,Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs,Confirmatory,23999140.0,
1589,774870,1,1,,103226686,446541,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Schmitt",Other,23999140.0,
1590,776764,1,1,,103226686,446541,Active,,,0.044000000000000004,IC50,Cytotoxicity against human PBMC after 72 hrs by MTT assay,Confirmatory,24121309.0,
1591,776765,1,1,,103226686,446541,Active,,,9.45,EC50,Antiproliferative activity against human Jurkat cells assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis,Confirmatory,24121309.0,
1592,776766,1,1,,103226686,446541,Active,,,5.9999999999999995e-05,EC50,Antiproliferative activity against human PBMC assessed as incorporation of [3H]thymidine after 18 hrs by scintillation counting analysis,Confirmatory,24121309.0,
1593,776767,1,1,,103226686,446541,Unspecified,,,,,"Selectivity index, ratio of IC50 to EC50 for human Jurkat cells",Other,24121309.0,
1594,776768,1,1,,103226686,446541,Unspecified,,,,,"Selectivity index, ratio of IC50 to EC50 for human PBMC",Other,24121309.0,
1595,776769,1,1,,103226686,446541,Active,,,28.21,IC50,Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay,Confirmatory,24121309.0,
1596,776770,1,1,,103226686,446541,Active,,,0.006999999999999999,Ki,Inhibition of human IMPDH,Confirmatory,24121309.0,
1597,977599,1,1,,103226686,446541,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1598,977602,1,2,,103226686,446541,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1599,977610,3,1,,46392307,446541,Active,15826575.0,,0.006,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,8681386.0,
1600,1053175,2,1,,124812223,446541,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
1601,1053197,1,1,,85148364,446541,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1602,1060472,1,1,,103226686,446541,Active,,,0.01,Ki,Binding affinity to human IMPDH,Confirmatory,24269162.0,
1603,1073348,1,1,,103226686,446541,Active,,,0.2,IC50,Inhibition of Chikungunya virus IMPDH,Confirmatory,24079775.0,
1604,1096461,1,2,,103226686,446541,Active,,,1.8,EC50,Antiviral activity against Vaccinia virus infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay,Confirmatory,,
1605,1115250,1,2,,103226686,446541,Active,,,1.8,EC50,Antiviral activity against Vaccinia virus infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay,Confirmatory,,
1606,1117298,1,2,,170465182,446541,Inactive,,,0.631,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1607,1117301,1,2,,170465182,446541,Inactive,,,0.2818,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
1608,1117302,1,2,,170465182,446541,Inactive,,,1.7783,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
1609,1117303,1,2,,170465182,446541,Inactive,,,1.13,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
1610,1117304,1,2,,170465182,446541,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1611,1117305,1,2,,170465182,446541,Inactive,,,7.9433,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1612,1117310,1,1,,170465182,446541,Inactive,,,0.630957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1613,1117311,1,1,,170465182,446541,Inactive,,,0.28183800000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
1614,1117312,1,1,,170465182,446541,Inactive,,,7.943280000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1615,1117314,1,1,,170465182,446541,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1616,1117315,1,1,,170465182,446541,Inactive,,,1.7782799999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
1617,1117318,1,1,,170465182,446541,Inactive,,,1.12202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
1618,1159389,1,2,,103226686,446541,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
1619,1159396,1,2,,103226686,446541,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
1620,1159399,1,2,,103226686,446541,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
1621,1159400,1,2,,103226686,446541,Unspecified,,,,,ASTRAZENECA: Second most acidic pKa value (pKa A2) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
1622,1159509,1,1,,170465182,446541,Inconclusive,119626539.0,4790.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1623,1159515,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1624,1159516,1,1,,170465182,446541,Inconclusive,119611100.0,22926.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1625,1159517,1,1,,170465182,446541,Active,,,16.9301,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1626,1159518,1,1,,170465182,446541,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1627,1159519,1,1,,170465182,446541,Inconclusive,119611100.0,22926.0,26.8325,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1628,1159520,1,1,,170465182,446541,Inconclusive,,,0.6682,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1629,1159521,1,1,,170465182,446541,Active,15928672.0,19885.0,0.1333,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1630,1159523,1,1,,170465182,446541,Active,15928672.0,19885.0,0.143968,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1631,1159524,1,1,,47193743,446541,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1632,1159524,1,1,,124882524,446541,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1633,1159524,1,1,,124882525,446541,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1634,1159525,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1635,1159526,1,1,,170465182,446541,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1636,1159527,1,1,,170465182,446541,Inconclusive,325495497.0,6256.0,3.7902,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1637,1159528,1,1,,170465182,446541,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1638,1159529,1,1,,170465182,446541,Inconclusive,,,0.674,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1639,1159531,1,1,,170465182,446541,Inconclusive,325495497.0,6256.0,0.301065,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1640,1159550,3,1,,252401962,446541,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
1641,1159551,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1642,1159552,1,1,,170465182,446541,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1643,1159553,2,1,,170465182,446541,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1644,1159555,1,1,,170465182,446541,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1645,1159580,2,1,,268734508,446541,Active,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1646,1159606,1,1,,85148364,446541,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1647,1159607,2,1,,312596430,446541,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1648,1159614,1,2,,170465182,446541,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1649,1159620,1,1,,103226686,446541,Active,,,,,Summary of drug indications.,Other,,
1650,1181041,1,1,,103226686,446541,Active,,,0.18,IC50,Immunosuppressive activity in anti-CD3/anti-CD28-induced human PBMC after 96 hrs by flow cytometry,Confirmatory,24963543.0,
1651,1181042,1,1,,103226686,446541,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC after 96 hrs by flow cytometry,Confirmatory,24963543.0,
1652,1186327,1,1,,103226686,446541,Active,,,0.2,CC50,Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay,Confirmatory,25082514.0,
1653,1186329,1,1,,103226686,446541,Active,,,42.0,CC50,Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay,Confirmatory,25082514.0,
1654,1186330,1,1,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay,Confirmatory,25082514.0,
1655,1186331,1,1,,103226686,446541,Unspecified,,,100.0,CC50,Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay,Confirmatory,25082514.0,
1656,1186332,1,1,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay,Confirmatory,25082514.0,
1657,1186333,1,1,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay,Confirmatory,25082514.0,
1658,1186334,1,1,,103226686,446541,Active,,,20.0,CC50,Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay,Confirmatory,25082514.0,
1659,1186335,1,1,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay,Confirmatory,25082514.0,
1660,1186336,1,1,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay,Confirmatory,25082514.0,
1661,1186337,1,1,,103226686,446541,Active,,,0.6,EC50,Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay,Confirmatory,25082514.0,
1662,1186339,1,1,,103226686,446541,Active,,,2.0,EC50,Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay,Confirmatory,25082514.0,
1663,1186340,1,1,,103226686,446541,Unspecified,,,100.0,EC50,Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay,Confirmatory,25082514.0,
1664,1186342,1,1,,103226686,446541,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Respiratory syncytial virus",Other,25082514.0,
1665,1204074,1,1,,103226686,446541,Active,,,19.0,CC50,Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method,Confirmatory,25913116.0,
1666,1204082,1,1,,103226686,446541,Active,,,1.5,EC50,Antiviral activity against Vaccinia virus infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay,Confirmatory,25913116.0,
1667,1210129,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,160.0,Km,Activity of human recombinant UGT1A9 expressed in insect cells assessed as enzyme mediated glucuronidation by LC-MS/MS method,Confirmatory,22238289.0,
1668,1211175,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Drug metabolism in human intestinal microsomes assessed as UGT1A9-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
1669,1211182,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Ratio of UGT1A9-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A9-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM,Other,22275465.0,
1670,1211189,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Ratio of UGT1A9-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT1A9-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM,Other,22275465.0,
1671,1211196,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Ratio of UGT1A9-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A9-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM,Other,22275465.0,
1672,1211203,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Drug metabolism in human liver microsomes assessed as UGT1A9-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin,Other,22275465.0,
1673,1211210,1,1,,103226686,446541,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin,Other,22275465.0,
1674,1211213,1,1,,103226686,446541,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase,Other,22275465.0,
1675,1211215,1,1,,103226686,446541,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin,Other,22275465.0,
1676,1211220,1,1,,103226686,446541,Unspecified,,,,,Ratio of unbound intrinsic glucuronidation clearance in human kidney microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human kidney microsomes in absence of bovine serum albumin,Other,22275465.0,
1677,1211222,1,1,,103226686,446541,Unspecified,,,,,Ratio of unbound intrinsic glucuronidation clearance in human intestinal microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human intestinal microsomes in absence of bovine serum albumin,Other,22275465.0,
1678,1211227,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Drug metabolism in human liver microsomes assessed as UGT1A9-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
1679,1211234,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Drug metabolism in human kidney microsomes assessed as UGT1A9-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
1680,1211237,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound glucuronidation in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
1681,1211239,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound glucuronidation in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
1682,1211241,1,1,,103226686,446541,Unspecified,,,,,Fraction unbound glucuronidation in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
1683,1211243,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound glucuronidation in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin,Other,22275465.0,
1684,1211245,1,2,,103226686,446541,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase,Other,22275465.0,
1685,1211248,1,2,,103226686,446541,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin,Other,22275465.0,
1686,1211251,1,1,,103226686,446541,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase,Other,22275465.0,
1687,1211254,1,2,,103226686,446541,Unspecified,,,,,Drug metabolism in human intestinal microsomes assessed as UGT1A8/2B7-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 2% bovine serum albumin,Other,22275465.0,
1688,1211260,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Ratio of UGT1A9-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A9-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 1% bovine serum albumin,Other,22275465.0,
1689,1211267,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Ratio of UGT1A9-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT1A9-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 1% bovine serum albumin,Other,22275465.0,
1690,1211274,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Ratio of UGT1A9-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A9-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM in presence of 1% bovine serum albumin,Other,22275465.0,
1691,1211278,1,1,,103226686,446541,Unspecified,,,,,Clearance in iv dosed human,Other,22275465.0,
1692,1211279,1,1,,103226686,446541,Unspecified,,,,,Renal clearance in human,Other,22275465.0,
1693,1211280,1,1,,103226686,446541,Unspecified,,,,,Fraction unbound glucuronidation in human plasma,Other,22275465.0,
1694,1211281,1,2,,103226686,446541,Unspecified,,,,,Ratio of drug level blood to plasma in human,Other,22275465.0,
1695,1211282,1,2,,103226686,446541,Unspecified,,,,,Fraction metabolized glucuronidation in human liver microsomes in presence of UDP-glucuronosyltransferase,Other,22275465.0,
1696,1211283,1,2,,103226686,446541,Unspecified,,,,,Fraction metabolized glucuronidation in human liver microsomes in presence of UDP-glucuronosyltransferase and bovine serum albumin,Other,22275465.0,
1697,1211284,1,2,,103226686,446541,Unspecified,,,,,Glucuronidation clearance in human liver microsomes,Other,22275465.0,
1698,1211285,1,2,,103226686,446541,Unspecified,,,,,Glucuronidation clearance in human liver microsomes in presence of bovine serum albumin,Other,22275465.0,
1699,1211287,1,2,,103226686,446541,Unspecified,29839451.0,54600.0,,,Drug metabolism in human kidney microsomes assessed as UGT1A9-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin,Other,22275465.0,
1700,1220783,1,1,,103226686,446541,Unspecified,,,,,Drug metabolism in human assessed as glucuronide concentration in bile and urine,Other,21282406.0,
1701,1220784,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound in mouse plasma by ultracentrifugation method,Other,21282406.0,
1702,1220785,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound in rat plasma by ultracentrifugation method,Other,21282406.0,
1703,1220786,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound in monkey plasma by ultracentrifugation method,Other,21282406.0,
1704,1220787,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound in dog plasma by ultracentrifugation method,Other,21282406.0,
1705,1220788,1,2,,103226686,446541,Unspecified,,,,,Fraction unbound in human plasma by ultracentrifugation method,Other,21282406.0,
1706,1220789,1,2,,103226686,446541,Unspecified,,,,,Ratio of drug level in blood to plasma in mouse,Other,21282406.0,
1707,1220790,1,2,,103226686,446541,Unspecified,,,,,Ratio of drug level in blood to plasma in rat,Other,21282406.0,
1708,1220791,1,2,,103226686,446541,Unspecified,,,,,Ratio of drug level in blood to plasma in monkey,Other,21282406.0,
1709,1220792,1,2,,103226686,446541,Unspecified,,,,,Ratio of drug level in blood to plasma in dog,Other,21282406.0,
1710,1220793,1,2,,103226686,446541,Unspecified,,,,,Ratio of drug level in blood to plasma in human,Other,21282406.0,
1711,1220794,1,1,,103226686,446541,Unspecified,,,,,Plasma clearance in human,Other,21282406.0,
1712,1220795,1,1,,103226686,446541,Unspecified,,,,,Plasma clearance in po dosed human,Other,21282406.0,
1713,1220796,1,1,,103226686,446541,Unspecified,,,,,"Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1714,1220797,1,1,,103226686,446541,Unspecified,,,,,Volume of distribution at steady state in human,Other,21282406.0,
1715,1220798,1,1,,103226686,446541,Unspecified,,,,,Half life in human,Other,21282406.0,
1716,1220799,1,1,,103226686,446541,Unspecified,,,,,"Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1717,1220800,1,1,,103226686,446541,Unspecified,,,,,"Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1718,1220801,1,1,,103226686,446541,Unspecified,,,,,"Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1719,1221821,1,1,,103226686,446541,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay,Other,20926620.0,
1720,1223422,1,2,,103226686,446541,Unspecified,,,,,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7*1c mutant-mediated intrinsic clearance of mycophenolic acid acyl glucuronide by HPLC and LC-MS/MS method,Other,21123165.0,
1721,1223423,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in non-diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1722,1223424,1,2,,103226686,446541,Unspecified,136727.0,7364.0,454.3,Km,Drug metabolism in non-diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1723,1223425,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in non-diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1724,1223426,1,2,,103226686,446541,Active,136727.0,7364.0,1.5,Ki,Uncompetitive substrate inhibition of UGT2B7 in non-diabetic human liver microsomes assessed as reduction in enzyme-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1725,1223427,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in non-diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1726,1223428,1,2,,103226686,446541,Unspecified,136727.0,7364.0,601.0,Km,Drug metabolism in non-diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1727,1223429,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in non-diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1728,1223430,1,2,,103226686,446541,Active,136727.0,7364.0,2.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in non-diabetic human liver microsomes assessed as reduction in enzyme-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1729,1223431,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1730,1223432,1,2,,103226686,446541,Unspecified,136727.0,7364.0,1009.0,Km,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1731,1223433,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in non-diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1732,1223434,1,2,,103226686,446541,Active,136727.0,7364.0,1.5,Ki,Uncompetitive substrate inhibition of UGT2B7 in non-diabetic human kidney microsomes assessed as reduction in enzyme-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1733,1223435,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1734,1223436,1,2,,103226686,446541,Unspecified,136727.0,7364.0,3015.0,Km,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1735,1223437,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in non-diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1736,1223438,1,2,,103226686,446541,Active,136727.0,7364.0,2.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in non-diabetic human kidney microsomes assessed as reduction in enzyme-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1737,1223439,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1738,1223440,1,2,,103226686,446541,Unspecified,136727.0,7364.0,481.6,Km,Drug metabolism in diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1739,1223441,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1740,1223442,1,2,,103226686,446541,Active,136727.0,7364.0,1.5,Ki,Uncompetitive substrate inhibition of UGT2B7 in diabetic human liver microsomes assessed as reduction in enzyme-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1741,1223443,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1742,1223444,1,2,,103226686,446541,Unspecified,136727.0,7364.0,502.3,Km,Drug metabolism in diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1743,1223452,1,2,,103226686,446541,Unspecified,,,,,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7*1c mutant-mediated intrinsic clearance of mycophenolic acid acyl glucuronide by HPLC and LC-MS/MS method,Other,21123165.0,
1744,1223453,1,2,,103226686,446541,Unspecified,,,,,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7*2 mutant-mediated intrinsic clearance of mycophenolic acid acyl glucuronide by HPLC and LC-MS/MS method,Other,21123165.0,
1745,1223454,1,2,,103226686,446541,Unspecified,,,,,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7*2 mutant-mediated intrinsic clearance of mycophenolic acid acyl glucuronide by HPLC and LC-MS/MS method,Other,21123165.0,
1746,1223455,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in diabetic human liver microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1747,1223456,1,2,,103226686,446541,Active,136727.0,7364.0,2.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in diabetic human liver microsomes assessed as reduction in enzyme-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1748,1223457,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1749,1223458,1,2,,103226686,446541,Unspecified,136727.0,7364.0,1158.0,Km,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1750,1223459,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid phenolic 7-O-glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1751,1223460,1,2,,103226686,446541,Active,136727.0,7364.0,1.5,Ki,Uncompetitive substrate inhibition of UGT2B7 in diabetic human kidney microsomes assessed as reduction in enzyme-mediated mycophenolic acid phenolic 7-O-glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1752,1223461,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1753,1223462,1,2,,103226686,446541,Unspecified,136727.0,7364.0,3431.0,Km,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1754,1223463,1,2,,103226686,446541,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in diabetic human kidney microsomes assessed as UGT2B7-mediated mycophenolic acid acyl glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
1755,1223464,1,2,,103226686,446541,Active,136727.0,7364.0,2.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in diabetic human kidney microsomes assessed as reduction in enzyme-mediated mycophenolic acid acyl glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
1756,1224834,3,1,,170465182,446541,Inconclusive,,,1.1883,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1757,1224835,1,1,,170465182,446541,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1758,1224836,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1759,1224837,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1760,1224838,1,1,,170465182,446541,Inconclusive,66775687.0,9970.0,0.5308,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1761,1224839,1,1,,170465182,446541,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1762,1224840,3,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1763,1224841,3,1,,170465182,446541,Active,325495545.0,2101.0,2.6603,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1764,1224842,3,1,,170465182,446541,Inactive,325495545.0,2101.0,2.371,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1765,1224843,1,1,,170465182,446541,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1766,1224844,1,1,,170465182,446541,Active,,,0.1509,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1767,1224845,1,1,,170465182,446541,Active,344243002.0,100757539.0,0.8748,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1768,1224846,1,1,,170465182,446541,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1769,1224847,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1770,1224848,3,1,,170465182,446541,Inactive,325495545.0,2101.0,0.1059,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1771,1224849,3,1,,170465182,446541,Inconclusive,325495545.0,2101.0,0.1059,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1772,1224857,2,1,,170465182,446541,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1773,1224859,2,1,,170465182,446541,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1774,1224863,1,1,,176483940,446541,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1775,1224863,1,1,,176484849,446541,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1776,1224863,1,1,,316920485,446541,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1777,1224865,1,2,,85148364,446541,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1778,1224867,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1779,1224868,1,1,,170465182,446541,Inconclusive,,,1.693,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1780,1224869,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1781,1224870,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1782,1224871,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1783,1224872,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1784,1224873,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1785,1224874,1,1,,170465182,446541,Inconclusive,,,1.5089,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1786,1224875,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1787,1224876,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1788,1224877,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1789,1224878,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1790,1224879,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1791,1224880,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1792,1224881,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1793,1224882,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1794,1224883,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1795,1224884,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1796,1224885,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1797,1224886,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1798,1224887,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1799,1224888,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1800,1224889,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1801,1224890,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1802,1224892,1,1,,170465182,446541,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1803,1224893,1,1,,170465182,446541,Active,66775687.0,9970.0,0.573149,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1804,1224894,1,1,,170465182,446541,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1805,1224895,1,1,,170465182,446541,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1806,1224896,1,1,,170465182,446541,Active,344243002.0,100757539.0,1.16657,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1807,1224905,2,1,,92308693,446541,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1808,1224905,2,1,,92308693,446541,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1809,1226487,1,1,,103226686,446541,Unspecified,,,,,Antiviral activity against Dengue virus type 2 New Guinea C infected in African green monkey Vero cells assessed as reduction in viral titer at 1 uM after 2 days by Giemsa staining assay relative to control,Other,25909386.0,
1810,1234127,1,1,,103226686,446541,Unspecified,,,,,Drug metabolism in rat liver microsomes assessed as glucuronide formation at 600 uM incubated for 30 mins in presence of UDPGA by LC-MS/MS method,Other,26110337.0,
1811,1234128,1,1,,103226686,446541,Unspecified,,,,,Drug metabolism in human liver microsomes assessed as glucuronide formation at 600 uM incubated for 60 mins in presence of UDPGA by LC-MS/MS method,Other,26110337.0,
1812,1246236,1,1,,103226686,446541,Unspecified,,,100.0,CC50,Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining,Confirmatory,26119992.0,
1813,1246240,1,1,,103226686,446541,Active,,,1.5,EC50,Antiviral activity against Human Vaccinia virus ATCC VR-1549 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining,Confirmatory,26119992.0,
1814,1259241,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1815,1259242,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1816,1259243,1,1,,170465182,446541,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1817,1259244,1,1,,170465182,446541,Inactive,348019627.0,2099.0,1.3333,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1818,1259247,1,1,,170465182,446541,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1819,1259248,1,1,,170465182,446541,Inconclusive,348019627.0,2099.0,1.33332,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1820,1259309,1,1,,124812223,446541,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1821,1259310,1,1,,321946018,446541,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1822,1259310,1,1,,333471961,446541,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1823,1259310,1,1,,333472377,446541,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1824,1259311,1,1,,124812223,446541,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1825,1259313,1,1,,47193743,446541,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1826,1259318,1,1,,85148364,446541,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1827,1259344,1,1,,144204161,446541,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1828,1259355,1,1,,144204161,446541,Inconclusive,,,1.7783,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1829,1259356,1,1,,144204161,446541,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1830,1259364,1,1,,170465182,446541,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1831,1259365,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1832,1259366,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1833,1259367,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1834,1259368,1,1,,170465182,446541,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1835,1259369,1,1,,170465182,446541,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1836,1259377,1,1,,170465182,446541,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1837,1259378,1,1,,170465182,446541,Inconclusive,54288833.0,2100.0,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1838,1259379,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1839,1259380,1,1,,170465182,446541,Active,,,0.1333,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1840,1259381,1,1,,170465182,446541,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1841,1259382,1,1,,170465182,446541,Inconclusive,,,0.1188,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1842,1259383,1,1,,170465182,446541,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1843,1259384,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1844,1259385,1,1,,170465182,446541,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1845,1259386,1,1,,170465182,446541,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1846,1259387,1,1,,170465182,446541,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1847,1259388,1,1,,170465182,446541,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1848,1259389,1,1,,124637737,446541,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
1849,1259390,1,1,,170465182,446541,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1850,1259391,1,1,,170465182,446541,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1851,1259392,1,1,,170465182,446541,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1852,1259393,1,1,,170465182,446541,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1853,1259394,1,1,,170465182,446541,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1854,1259395,1,1,,170465182,446541,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1855,1259396,1,1,,170465182,446541,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1856,1259400,1,1,,170465182,446541,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1857,1259401,1,1,,170465182,446541,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1858,1259402,1,1,,170465182,446541,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1859,1259403,1,1,,170465182,446541,Inconclusive,325495545.0,2101.0,0.10590899999999999,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1860,1259404,1,1,,170465182,446541,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1861,1259407,1,1,,363903515,446541,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1862,1259408,1,1,,363897076,446541,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
1863,1259416,1,2,,340081994,446541,Inconclusive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1864,1259416,1,2,,375174594,446541,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1865,1259421,1,1,,340081994,446541,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1866,1259421,1,1,,375174594,446541,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1867,1259423,1,2,,354915591,446541,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1868,1259423,1,2,,354993348,446541,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
